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Abstract	  
Solid form screening and selection of pharmaceutical parent compounds (PCs) has been 
identified as a critical step in the early stages of drug development.  A significant fraction of 
candidate PCs are rejected on account of poor physicochemical properties that affect their 
biopharmaceutical attributes such as bioavailability, toxicity, and stability.  As a result, there is a 
pressing need to characterize these physicochemical properties early in the drug development 
process by exploring (1) all possible solid forms of a PC, and (2) the conditions favorable for 
formulation of these solid forms.  While automated robotic systems have been developed to 
execute high throughput screens, these robotic tools typically require larger quantities of PC for 
solid form screening (~ 5 mg of material per condition) than are typically available in the initial 
phases of the drug development pipeline.  Microfluidics has the potential to screen PCs using 
significantly smaller quantities of materials (~5 µg per condition), thereby enabling high 
throughput screening for suitable solid forms at the crucial early stages of development when 
only limited amounts of PC (typically 10 mg) are available.  Here, we present PDMS-based 
microfluidic platforms that allow combinatorial mixing of PC and counter ion solutions in arrays 
of 24-48 sub-microliter wells enabling solid form screening by different modes of crystallization, 
viz. diffusive mixing, antisolvent addition, and solvent evaporation.  These platforms are 
compatible with a wide range of solvents typically used for pharmaceutical crystallization, suffer 
from minimal solvent loss (enabling long-term experiments), allow improved control over 
solvent evaporation, and enable portability between sample loading and analysis stations.  
Additionally, these platforms enable on-chip characterization of the solid forms by Raman 
spectroscopy, circumventing the need to manually harvest crystals.  The platforms were 
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validated with several model compounds namely, naproxen, ephedrine, indomethacin, caffeine, 
theophylline, and tamoxifen.  The microfluidic platforms developed here find immediate 
application in the pharmaceutical industry, as they require cheap and readily available external 
peripherals, such as pipettes and a vacuum source for operation. 
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Chapter 1 
INTRODUCTION 
1.1. Challenges in drug development in the pharmaceutical industry 
Increasing development costs, long turnaround times, lack of rich pipelines, stringent 
regulatory policies, and loss of revenue to generic manufacturers due to patent expiration have 
resulted in insufficient revenue and profits for the pharmaceutical industry.1  Therefore, 
accelerating the drug development pipeline without corresponding peaks in production costs is 
recognized as a major priority for the pharmaceutical industry.2  “Time-to-market” is defined as 
the time period between nomination of a novel drug candidate and its subsequent approval by the 
Food and Drug Administration (FDA) and commercialization.  An average estimate of this for 
all drugs approved until 2002 by the FDA reported as 12 years and 10 months.3  Figure 1.1shows 
the various stages of drug development, along with the approximate time expended in each 
stage.2  As a consequence, the cost of drug development has been steadily increasing over the 
past 30 years ($138 million in 1975 to $1.3 billion in 2005 as shown in Table 1.14,5).  Increasing 
health care standards and stringent regulations necessitate more extensive research and 
development, which further lengthen the time and increase the cost of development, thereby 
affecting the profits of the pharmaceutical companies.   
The pharmaceutical industry also suffers from the attrition of drugs2,3,5,6, which is 
prevalent throughout the drug development pipeline (Figure 1.22).  Attrition refers to the loss of 
candidate drugs due to lack of desirable physicochemical and biopharmaceutical properties, high 
levels of toxicity, and poor drug efficacy.3  Figure 1.3 shows the various stages of drug 
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development from discovery to launch with special emphasis on process R&D.2  Following 
identification of lead candidates with desirable pharmacological properties, they are extensively 
screened for lead optimization of candidate drugs (CD).  At this stage, 93.3% of the CDs are 
rejected.2  CDs that make it to the preclinical development stage are further investigated for 
scalability of production, intellectual property, and cost economics.2  90% of the compounds that 
enter this stage fail, leading to 0.67 % of the original compound library being available for 
clinical studies (phases I, II, and III).2  Only 0.04% of the original compounds make it past 
clinical studies, 0.027% are federally approved, and amongst them 0.003% of the drugs provide a 
satisfactory return on investment.2  While greater than 50% of the candidate drugs entering 
clinical trials are lost due to efficacy and safety concerns, nearly 40% is lost due to patent issues 
and poor biopharmaceutical and physicochemical properties (as shown in Figure 1.23).6  The 
intrinsic biological efficiency of an active pharmaceutical ingredient (API) is determined by the 
nature of its interaction its physiological targets (e.g., receptors and enzymes).  However, the 
ability to synthesize, store and administer the drug to the patient in a safe, stable, and cost-
effective manner depends largely on the physicochemical and materials properties of the 
compound in the solid state viz. solubility, ionization constant, surface activity, stability and 
lipophilicity.6,7,8 
In the quest to accelerate the drug development process, pharmaceutical companies have 
prioritized strengthening the discovery and development interface by the incorporation of a 
“developability screen”.1,9  A developability screen entails conducting sufficient preclinical 
studies to assess physicochemical properties of the CDs in the selection phase itself.1  The 
developability screen aids in the selecting against CDs that do not have high probabilities of 
success by virtue of possessing suboptimal physicochemical properties.9,10  Additionally, the 
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knowledge gained during the developability screen is useful in rapid development of optimal 
drug formulations, storage, and delivery strategies reducing the cost of development and time-to-
market.1  Early screening allows researchers to prioritize the selection of candidate drugs based 
on (a) their probability of success in the drug development process and (b) their potential for a 
positive return on investment, as it will aid in minimizing the R&D costs associated with drugs 
that otherwise will fail at a later stage. 
Key physicochemical attributes that are crucial to designing successful developability 
screens and minimizing rates of candidate drug attrition are briefly described as follows:  
Solubility affects dissolution rates, solvent compatibility, toxicity, uptake rates and 
consequently the bioavailability of the drugs.8,11,12  Solubility evaluation for drugs in various 
types of media (e.g., water, different pH buffers, simulated physiological fluids) is employed to 
eliminate compounds with very limited solubility.6,8  
The ionization constant (pKa) determines the effect of solvent pH on solubility, and 
dissolution rates of CDs as well as critical physiological properties, such as behavior of drugs 
when in different pH environments within cells and tissues, e.g., the very low pH state inside 
human stomach.8  Additionally, ionizable compounds can form salts (with counter ions), which 
may have improved solubility, hygroscopicity, solid-state stability, permeability or potential for 
polymorphism.8,13  
Surface activity refers to presence of hydrophilic and hydrophobic groups on drugs that 
typically increase the solubility in aqueous media via micelle formation or other aggregation.  
However, surface activity can also lead to disruption of cell membranes, thus rendering drugs 
toxic.8  In this way, surface activity can be either helpful or harmful. 
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Stability of a compound in a variety of pharmaceutical situations (e.g., photo-, oxidative-, 
pH dependent-, solid-state stability) determines its shelf-life and drastically affects its potential 
for reaching the market.1,8  
Characterization of the afore-mentioned physicochemical properties necessitates 
identification of all the available solid forms of the drug.  This requires initiation of solid form 
screening as early as possible in the drug development process.  Inadequate selection of 
crystalline forms selections has resulted in withdrawal of products from the market (e.g., 
ritonavir14) and insufficient solid form screening information has led to patent litigation.15,16  
CDs can exist in a variety of distinct solid forms, including polymorphs, solvates, hydrates, salts, 
cocrystals, and amorphates as shown in Figure 1.5.17  Each form has unique physicochemical 
properties that can profoundly influence the bioavailability, manufacturability, stability and other 
performance characteristics of the drug.7,10,13,18  The different kinds of solid forms are described 
as follows:  
Salts: Salt formation is an acid/base reaction where either a proton transfer or a 
neutralization reaction takes place.  Nearly 50% of the drugs are marketed as salt forms.19  Salt 
forms can affect solubility (aqueous), permeability, hygroscopicity, and processability of an 
ionizable drug candidate (acid or base), thereby providing an effective means to balance the 
requirements of bioavailability, stability, manufacturability, and patient compliance.20-22  A salt 
with adequate solubility and stability reduces pharmacokinetic variations, increases exposure and 
toxicological coverage, and enables simple formulations (powder) to be used in preclinical and 
clinical studies.12,23,24  Several lead compounds identified by combinatorial and high-throughput 
screening strategies tend to get eliminated on account of very poor aqueous solubilities (< 1 
µg/ml).12  Therefore, drugs are screened with a variety of pharmaceutically acceptable counter 
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ions (~69 cations such as arginine, pyridine, Na+ and ~21 anions such as succinate, citrate, 
tartrate13) for salt formation.  This salt screening process results in identification of an increased 
number of solid forms enhancing the chances of forming a solid form with desirable 
characteristics.  For formation of a stable salt there should be a minimum difference of about 3 
units between the pKa value of the drug and the counter ion, although in some cases salts are 
found to be stable when this difference is greater than 3 units.20  The criterion is especially 
important when the drug substance is a particularly weak acid or base.  Figure 1.612 shows the 
pH-solubility dependence of free acid/base and its salt.  There is an upper limit to the pH value 
(pHmax) value in case of both acid and base beyond which only the salt exists, and the solubility 
of the salt is limited by its solubility product (Ksp). 
Cocrystals: Cocrystals are multi-component assemblies held together by freely 
reversible, non-covalent interactions.  In most cases, they offer a different crystallization route as 
compared to salts, whereby a drug regardless of absence or presence of ionizable groups can 
potentially be crystallized.17,19,25  This pathway complements existing methods by enabling 
introduction of molecules with undesirable pharmaceutical profiles (due to their non-ionizable 
functional groups) to the screening process.17  A larger number of non-toxic cocrystal formers 
(e.g., weak carboxylic acids such as 2,5-dihydroxy benzoic acid, 2-hydroxy benzoic acid) exists 
vis-à-vis salt formers, resulting in the possibility of many cocrystal forms in comparison to salts.  
Cocrystals form when the pKa difference between the drug and its counter ion less than 0 in 
which case proton transfer does not take place between the acidic and basic functional groups 
and a continuum exists between the two states with protons non-covalently bound by hydrogen 
bonding.  Since structural integrity of the drug is preserved, co-crystallization is an attractive 
route enabling for obtaining solid forms with enhanced bioavailability, improved stability 
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(resistance to hydrate formation), and improved solubility of poorly soluble, neutral 
drugs.19,17,18,25  Figure 1.7 illustrates a possible multicomponent systems including cocrystals, salt 
cocrystals, and salts along with their respective hydrates and solvates.17 
Polymorphs:  Polymorphism is the ability of a compound to crystallize into different 
crystalline structures exhibiting varied physical properties such as stability, solubility, and 
dissolution rate.6,16  Screening and characterization of polymorphs of drugs, their salts, and 
cocrystals is important due to their significant impact on drug properties and performance.2,16,18 
The unpredictable nature of polymorphism demands early and thorough examination of solid 
forms to identify the most stable polymorph and hence, minimize unforeseen risks in drug 
development like in the case of ritonavir16 where, a thermodynamically more stable form was 
discovered after some time of its launch and hence, the drug had to be retracted from market. 
Hydrates: Hydrates are nonionic supramolecular complexes formed between water and 
drug molecules.  Hydrate formation stabilizes the crystal structure via intermolecular bonding in 
the crystal lattice, resulting in stability in aqueous solution surroundings, below dehydration 
temperature).  Therefore, hydrates are often selected as the preferred solid form for development.  
Hydrates are also chosen for development to avoid hydrate formation in case of other solid forms 
during downstream processing, however, they suffer from risk of dehydration.26 
Solvates: Solvates are nonionic supramolecular complexes formed between the solvent 
and the drug molecules.  Like hydrates, they stabilize the crystal structure via intermolecular 
bonding in the crystal lattice and are thus stable in solvent surroundings.26 
Amorphates: Amorphates usually do not have well-defined crystalline structure.  
Amorphous forms are thermodynamically metastable, possess improved molecular mobility 
which results in better oral bioavailability.  However, they are not preferred as drug candidates as 
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their high mobility and hygroscopicity result in chemical and physical instability and 
consequently shorter shelf lives.26 
Early screening requires identification of all the available solid forms of a drug2 and 
conditions favoring their crystallization.  In addition, this information would enable nucleation of 
larger crystals, for characterizing their physicochemical and preformulation properties.  Such 
studies early in the development phase will aid in better selection of candidate drugs that proceed 
to clinical screening stages and reduce attrition rates in the later phases.  Screening for solid 
forms needs to (1) be initiated sooner in the R&D process, (2) include a more exhaustive set of 
conditions to ensure identification of all solid forms, and (3) consume less material so testing for 
the aforementioned properties can commence well before production is scaled up. 
 
1.2. Present challenges in solid form screening of pharmaceuticals 
The advent of combinatorial chemistry, high-throughput screening and technical 
advancements has resulted in many more biological targets and potential developmental 
candidates with adequate pharmacological and acceptable toxicological properties.10,27  
However, most of these candidates have sub-optimal physicochemical properties that include 
solubility, stability, and surface activity as well as preformulation challenges such as solution 
vehicles and toxicity, which results in long development times and attrition.2  Therefore, 
screening for physicochemical and preformulation properties of these drugs early in the 
development process is necessary.  Screening will improve selection of candidates for 
development, hence minimizing the overall development times and costs.  The first step in this 
process involves identifying all the solid forms and the conditions favorable for crystallization, 
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which entails extensive screening due to large number of variable parameters such as solvents, 
pH, precipitants, counterions, rate of evaporation, temperature, antisolvents and mixing 
mode.6,18,22,24 
Solid form screening for pharmaceuticals is severely limited by the small quantities of 
drugs (~ few milligrams) typically available during the early stages of development (due to the 
lengthy and expensive drug synthesis procedures).  Extensive screening requires minimal 
material consumption per screen, while maintaining a high level of consistency and accuracy in 
testing.  Conventional approaches involve mixing candidate drug solutions with precipitants 
(counter ion or antisolvent) manually in micro-well plates, which are then monitored for crystal 
formation. This requires large sample volumes (~ 1-2 ml per condition) and hence, significant 
quantities of the drug.23  Manual screening is time consuming and limits the number of 
conditions that can be screened in the early stages of development.23,28  Robotic systems are 
capable of automated, combinatorial liquid handling and are routinely employed by 
organizations such as Symyx, Transform pharmaceuticals, Avantium, and Anachem for solid 
form screening.23  Figure 1.8 shows an example of a robotic system developed by Symyx.28  
These robotic systems enable a high-throughput workflow that allows crystallization, salt 
selection, and polymorph studies to be completed in less time while consuming smaller 
quantities of the drug.23,28  Although, robotic manipulation enables faster, more accurate, less 
wasteful (of sample) combinatorial screens to be conducted as, and allows for screening of more 
conditions compared to manual screening, the screening process still commences at a later stage 
of development when ~ 1 g of drug is available.  The number of conditions that can be screened 
is with significantly small quantities of the drug available during the early stages of development 
(~ 10 mg) is still limited.28  Microfluidics has the potential to allow screening of candidate drugs 
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with sub-microliter volumes and allow better control over mixing of drug and counter 
ion/antisolvent solutions4,29 enabling screening of many more conditions with limited amounts of 
drug in the early stages of development.   
 
1.3. Microfluidic approaches for solid form screening of pharmaceuticals 
The development of a high throughput microfluidic platform for solid form screening can 
aid in identifying a large number of available solid forms of candidate drugs in the early phases 
of drug development.  This will further help in early investigation of physicochemical properties 
that affect solubility, bioavailability, dissolution rate and other parameters of the candidate drugs.  
Working with microfluidics has advantages that include reduced sample volume, reduced 
peripheral equipment, lower cost and improved control over fluid mixing.  
Microfluidics has progressed rapidly over the last few decades to the point that very large 
scale integrated (VLSI) microfluidic platforms allowing precise control over mixing and on-chip 
metering have been developed29,30 for crystallization studies of small pharmaceutical molecules 
as well as biological macromolecules such as proteins.4,31-36  Hansen et al.4 have developed 
highly integrated platforms for screening crystallization conditions of proteins using free 
interface diffusion, while utilizing sub-microliter volumes per condition (Figure 1.9 a1-a3).  
These platforms use normally open valves, which use positive pressures to meter fluid and 
maintain adjacent chambers isolated after mixing.  Laval et al.33,34 and Zheng et al.37 have 
developed water-in-oil emulsion based nanoliter volume droplets to screen for polymorphs and 
solubility by employing temperature control and to screen for protein crystallization conditions 
respectively (Figure 1.9 b1-b4).  Du et al.31 also developed a well-based system made of glass, 
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called “Slip-Chip”, in which preloaded precipitants mix diffusively with protein solutions 
(Figure 1.9 c1-c3).  Talreja et al.35 developed a microfluidic platform to screen conditions for 
protein crystallization by control over the solvent evaporation rates (Figure 1.9 b5,b6).  Lee et al. 
38 developed a micro scale platform with confined surfaces for crystal habit and polymorph 
screening.  While each of these approaches advance the capability of microfluidics to screen for 
crystallization conditions, they suffer from at least one of the following limitations: solvent 
incompatibility with organic solvents39, poor well-to-well isolation, limited portability due to 
required peripheral connections, and/or limited compatibility with analytical tools such as Raman 
spectroscopy and X-ray diffraction.40   
 
1.4.  Overall objectives  
The overall objective of our research is to develop microfluidic platforms for solid form 
screening of pharmaceuticals enabling improved screening efficiency.  Use of sub-milligram 
sample sizes of PC per condition will allow initiation of exhaustive screening earlier in the drug 
development process when typically ~10 mg of the drug is available, enabling acquisition of 
more information regarding the solid forms of the drug.  This information will further help 
researchers in early identification of solid forms with higher probabilities of having short R&D 
timelines and good returns on investment.   
This thesis presents microfluidic platforms for screening a wide range of solid forms for 
conditions favoring their crystallization.  Chapter 2 discusses the design, fabrication, operation 
and validation of hybrid microfluidic platforms (PDMS/cyclic olefin copolymer, COC) for solid 
form screening of PCs via free interface diffusion, temperature control, or antisolvent addition.  
Chapter 3 discusses the design, fabrication, operation and validation of hybrid microfluidic 
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platform (PDMS/COC/thiolene) for solid form screening of PCs via controlled evaporation of 
the solvent.  The platforms developed are compatible with polar solvents typically used in the 
pharmaceutical industry and with on-chip Raman spectroscopy allowing for characterization of 
the solid forms.  Chapter 4 discusses the challenges of designing microfluidics sufficiently 
resistant to organic solvents commonly used in the pharmaceutical industry.  Current progress in 
developing a high throughput solvent resistant platform with glass substrates is also included.  
Finally, Chapter 5 summarizes the key conclusions from this work and describes the future 
directions of this project. 
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1.5. Figures and Tables 
 
Figure 1.1: The Research and development process (Figure adapted from PhRMA profile 2011) 
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Figure 1.2: Attrition works against you: A schematic presentation of the likelihood of project 
surveillance at discrete stages along the R&D time line.  ROI, return on investment (Figure 
adapted from Federsel, 20032) 
 
 
Figure 1.3: From discovery to launch, the R&D phases in the pharma industry, with special 
emphasis on process R&D (Figure adapted from Federsel, 20032) 
 
14	  
	  
 
Figure 1.4: Reasons for attrition (1991-2000).  PK, pharmacokinetics (Adapted from Kola et al., 
20043) 
 
Figure 1.5: Pictures displaying the more common solid-state strategies and their respected 
components.  (Figure adapted from Schultheiss et al., 200917) 
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Figure 1.6: Schematic representation of the pH-solubility profile of a (a) basic drug and (b) 
acidic drug indicating that the solubilities may be expressed by two independent curves and that 
the point where two curves meet is the pHmax (Figure adapted from Serajuddin, 200712)    
 
Figure 1.7: Possible multi-component systems: cocrystals, salt cocrystals, and salts along with 
their respective solvate/hydrate forms.  (Figure adapted from Schultheiss et al., 200917) 
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Figure 1.8: Example of a SYMYX system used for crystallization screening. This highly complex 
robotic system used robotic pipettes to meter fluids into wells and perform crystallization studies 
(http://symyx.desantisbreindel.com/popups/module_coremodule.php) 
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Figure 1.9: Microfluidic chips for protein crystallization (a) Microfluidic chip to implement three 
different ratios for free interface diffusion assays (a1) Schematic showing loading of protein and 
precipitant (a2) Free interface diffusion on-chip (b) A droplet-based system and PDMS-based 
platform to allow gradual solvent evaporation. (b1) A schematic of the device. After the droplets 
containing the crystallization trials are formed, the trials are flowed into a glass capillary, flow is 
stopped, and crystallization takes place (b2) A microphotograph illustrating droplet formation 
(b3) A picture of the device (b4) Protein crystals obtained using this device. (b5) Schematic of 
the evaporation platform: a compartment with a drop containing protein and precipitant, 
connected to the atmosphere through an evaporation channel (b6) Optical micrograph of 
multiple wells cast in a single polymer slab. Scale bar: 2 mm (c) A SlipChip well based system. 
Schematics showing (c1) the loading of protein and mixing of protein with precipitant on-chip. 
(c2) Micrograph of loading green food dye (protein) into the chip and bringing it in contact it with 
colored solutions (precipitants) thus setting up the trial. (c3) Crystals of photosynthetic reaction 
center grown on the SlipChip. (Figures adapted from Li et al., 201041, Hansen et al., 20034, 
Talreja et al. 200535, Zheng et al. 200432) 
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Table 1.1: Cost to develop a drug 
Year Cost of drug development 
2005 $1.3 billion5 
2001 $802 million4 
1987 $318 million4 
 1975 $138 million4 
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Chapter 2 
HYBRID MICROFLUIDIC PLATFORMS FOR SOLID FORM SCREENING 
OF PHARMACEUTICAL PARENT COMPOUNDS VIA FREE INTERFACE 
DIFFUSION (FID), ANTISOLVENT ADDITION AND/OR TEMPERATURE 
CONTROL 
2.1.  Introduction  
Solid form screening (e.g., salts, cocrystals, and polymorphs) involves testing multiple 
crystallization conditions (e.g., reactive crystallization, temperature control, solvent evaporation, 
slurry conversion, antisolvent addition) with different counter ions (salt formers (SFs) or 
cocrystal formers (CCFs)).1-7  In the case of reactive crystallization, use of microfluidic 
platforms for mixing of the reacting components via free interface diffusion has enabled better 
control over mixing as well as over rates of supersaturation in comparison to traditional well-
plates based screening methods.8-11  Temperature control has also been proved to be a valuable 
tool in the case of polymorph screening and generating solubility curves.12-16  Microfluidics have 
enabled the development of very large scale integrated systems (VLSI)17,18 allowing the 
screening of many conditions such as crystallization of small molecules, proteins and salts of 
pharmaceutical parent compounds (PCs) using limited amount of PC.8,10-13,19  In this chapter, (a) 
characteristics of an ideal microfluidic platform for pharmaceutical solid form screening and (b) 
the design, fabrication, operation and validation of different PDMS-based microfluidic platforms 
will discussed.  The developed platforms employ free interface diffusion, antisolvent addition 
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and temperature control as different methods of crystallization for salt, cocrystal, and polymorph 
screening. 
2.2.  Characteristics of an ideal pharmaceutical screening platform 
The important considerations for designing a microfluidic platform for solid form 
screening are as follows: 
Solvent compatibility:  Many crystallization conditions often require solvents.  Therefore, 
compatibility with a wide range of solvents, particularly organic solvents, is a major 
consideration for material selection for the microfluidic platforms for pharmaceutical 
crystallization.  Solvent absorption and solvent loss via evaporation potentially limits the 
application of traditional PDMS-based microfluidic platforms for PC crystallization screening.20  
Cyclic olefin copolymer (COC) is known to have excellent resistance to several non-polar 
organic and aqueous solvents.21,22  Incorporation of materials with low permeability (e.g., COC), 
solvent resistant materials (e.g., Teflon), or surface treatment of PDMS (e.g., glass coating, 
CYTOP) allows drastic reduction or elimination of solvent loss in the microfluidic device 
enabling compatibility with a wide range of solvents.23-28 
Compatibility with optical microscopy: The device should be optically transparent 
allowing for visualization of the solid forms.  PDMS-based microfluidic devices have the 
advantage of being optically transparent.  Incorporation of other materials (e.g., COC and crystal 
clear tape with excellent optical clarity29) ensures convenient visualization via bright field 
imaging or Raman spectroscopy. 
Raman compatibility: Raman spectroscopy, Infrared spectroscopy or X-ray analyses are 
routinely used to confirm the identity of the solid forms crystallized on-chip.  Raman analysis 
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allows rapid and high throughput identification of the crystal forms2,7,30 and was chosen as the 
analytical technique for characterizing the solid forms.  For on-chip Raman analysis, the 
materials of microfluidic chips should have minimum background noise ensuring high signal to 
noise ratio. 
 
2.3.  Fabrication of FID-based PDMS microfluidic platforms  
2.3.1. Standard multilayer PDMS platform 
The crystallization platform comprised a thin multilayer PDMS device fabricated using 
standard multilayer soft lithographic procedures reported previously with several modifications 
explained later.8,17  Masters for the fluid layer and the control layer were created on silicon 
wafers (University Wafers, Boston, MA) patterned with SU-8 2050 photoresist (MicroChem 
Corporation, Newton, MA) using standard photolithography (50µm tall microchannels).  The 
photolithography masks for the silicon masters for the different layers were designed in 
Macromedia Freehand MXTM (Macromedia Inc.) and printed on high-resolution transparencies 
(5080 dpi, University of Illinois at Urbana-Champaign Printing Services).  A monolayer of 
(tridecafluoro-1, 1,2,2-tetrahydrooctyl) trichlorosilane (Gelest, Inc., Morrisville, PA) was 
deposited onto the silicon masters prior to replica molding in order to prevent covalent adhesion 
of PDMS onto photoresist and the silicon substrates. 
The fluid layer (75µm thickness) was prepared by spin coating 15:1 PDMS (General 
Electric RTV 615 Part A/B, Waterford, NY) on the fluid layer master at 1300 rpm, where 15:1 
(A: B) refers to the ratio of PDMS monomer to the cross-linker.  The control layer was prepared 
by pouring 5:1 PDMS onto the control layer master to attain a height of approximately 2 – 3 mm.  
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The two layers were partially cured by heating them at 65°C for approximately 30 minutes.  The 
partially cured control layer mold is then removed from the control layer master.  Holes were 
punched with a 20-gauge needle (B-D Precision Slide) at the inlets of the control layer.  The 
control layer mold was aligned manually on the fluid layer under an optical microscope (Leica 
MZ6).  The assembled device was then heated at 65°C for 4-12 hours to bond the control and the 
fluid layers.  The assembled device was then peeled off the fluid layer master, and holes were 
punched with a 20-gauge needle at the inlets and the outlets of the fluid layer.  As PDMS tends 
to contract on cooling, the features in the control later were designed to be 101.7% of the desired 
features in case of thick control layer devices.31  The assembled device is then covered with 
ScotchTM tape (3M) to protect from dust.  The device is then assembled by reversibly bonding it 
with pre-cleaned 3” x 2” glass slides (Fischer Scientific 12-550-A3).  
 
2.3.2.  Platform 1: Crystal clear tape/PDMS/PDMS/glass-based microfluidic platform 
The masters for the control and the fluid layer were fabricated as described in section 
2.3.1.  The fluid layer (75µm thickness) was prepared by spin coating 15:1 PDMS on the fluid 
layer master at 1300 rpm.  The thickness of the control layer was reduced to 85 µm by spin 
coating the 5:1 PDMS at 1100 rpm.  The two layers were partially cured by heating them at 65°C 
for approximately 30 minutes.  A PDMS frame (a 2.5” square slab with a 2” by 1” window in the 
centre) was prepared by pouring 10:1 PDMS on a blank silanized silicon wafer and was partially 
cured at 65°C for 30 minutes.  Next, this PDMS was bonded to the control layer mold by heating 
at 65°C for 30 minutes, to provide rigidity and allow for transfer of the control layer.  To avoid 
tearing of the control layer while peeling, 2 ml of hexane was poured onto the control layer to 
swell the thin PDMS control layer and aid in its removal from the control layer master.  The 
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control layer mould was then rinsed with water to remove residual hexane and dried.  Rinsing 
with water and drying led to contraction of the PDMS layer back to its original size.  Holes were 
punched with a 20-gauge needle at the inlets and outlets of the control layer and the control layer 
mold was aligned manually on the fluid layer under an optical microscope (Leica MZ6).  Crystal 
Clear Tape (Hampton HR4-511), which is impermeable to solvents, was stuck to the top of the 
combined control and fluid layers.   
Version 1: In a preliminary version of the device, PDMS (10:1 A:B) was poured in the 
window subsequent to adhesion of crystal clear tape onto the control layer.  The whole device 
was then heated at 65°C for 4 - 12 hours to allow for bonding of the control and the fluid layer.  
The assembled device was then peeled off the fluid layer master and holes were punched at the 
inlets and the outlets of the fluid layer using a 20-gauge needle.  The final device was placed on 
pre-cleaned 3” x 2” microscope slides when experiments were done using aqueous solutions.  
Incorporation of normally closed valves, which are actuated via negative pressure, permitted 
reversible bonding of the device with glass aiding in better adhesion with glass and minimizing 
leakage for aqueous solvents.32-34  Figure 2.1(b) illustrates the fabrication pipeline for the device.  
When polar organic solvents were used with the reversibly bonded device, it de-sealed 
and leaked due to solvent absorption and swelling of the PDMS.  Hence, the device had to be 
selectively bonded to the microscope slide such that the valve stops in the fluid layers are not 
bonded permanently.  To achieve selective irreversible bonding, all the valves were actuated, so 
that the valve stops do not contact the glass substrate during bonding.  The surface of the 
assembled device containing the microfluidic channels and the glass substrate were treated with 
atmospheric plasma consisting of oxygen and helium (1:75 volumetric ratio) using a plasma pen 
(Surfx technologies, AtomfloTM plasma) at 100 W for 2-4 seconds each.  Immediately following 
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treatment with the plasma pen, the PDMS device and the glass microscope slides were brought 
into contact and the valves were left actuated for approximately 6-8 hours, after which the PDMS 
device was irreversibly bonded to glass only in the channel areas.35,36 
Version 2: In this version of platform 1, after the alignment of the control layer over the 
fluid layer, the whole device was heated at 65°C for 4-12 hours to allow for bonding of the 
control and the fluid layer.  The assembled device was then peeled off the fluid layer master and 
holes were punched at the inlets and the outlets of the fluid layer with a 20-gauge needle.  Pre-
cleaned microscope slides were used as substrates in the case of experiments requiring imaging 
with bright field microscopy or a cross-polarizer.  No de-sealing and leakage was observed with 
polar solvents, if air pockets were avoided while bringing the assembled device in contact with 
the substrate.  Improved adhesion of flat conformal thin PDMS layers over glass compared to 
thick PDMS layers (version 1), resulted in better well-to-well isolation.  Using a thin layer of 
PDMS as the control layer minimizes the contraction in PDMS and hence, stretching of the 
dimensions of the PDMS control layer to account for PDMS shrinkage was not required.  Figure 
2.1a depicts the fabrication flow for the device.   
To enable imaging and analysis with Raman spectroscopy for both versions of platform 
1, the glass substrate was coated with thin layers of chromium and gold.  Pre-cleaned microscope 
slides were coated with a 20 nm layer of chromium and on top of the chromium, a 200 nm layer 
of gold using an E-beam evaporation system (Temescal six pocket E-Beam Evaporation 
System).  
2.3.3.  Platform 2: COC/PDMS/PDMS/COC (Hybrid microfluidic platform) 
The hybrid microfluidic chip consists of a COC backing layer, thin PDMS fluid and 
control layers, and a COC substrate.  The masters for the control and the fluid layers were 
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created as described in section 2.3.1.  The fluid layer (75 µm) and the control layer (85 µm) were 
prepared by spin coating 15:1 PDMS on the fluid layer master at 1300 rpm and 5:1 PDMS on the 
control layer master at 1100 rpm.  The two layers were partially cured by heating them at 65°C 
for approximately 30 minutes.  2mil (50 µm) COC film (6013 grade, TOPASTM Advanced 
Polymers Inc.) was bonded irreversibly to the top of the control layer mold by treatment with 
oxygen plasma.35,37  The control layer and the COC sheet were set in the plasma cleaner (Harrick 
Plasma, Extended model).  The chamber was evacuated to 500 mTorr of atmospheric gases, and 
exposed to oxygen plasma under the “high” setting (30 W) for 60–75 seconds to activate the 
PDMS and COC surfaces with hydroxyl groups.  After exposure, the COC sheet was placed on 
the control layer mold, avoiding air pockets and then heated at 65°C for 20-30 minutes.  The 
control layer bonded to the COC sheet was then carefully removed from the control layer master.  
The features side of the control layer was covered with ScotchTM tape (3M) in order to protect 
the layer from damage and dust during drilling.  Inlets for the control layer were drilled using a 
750µm drill bit (McMaster-Carr) in a Dremel 300 series drill.  The control layer was then 
manually aligned onto the fluid layer.  The assembled device was then heated first at 80°C for 
10–20 minutes on a hot plate to avoid air pocket formation between the control and fluid layers, 
followed by heating at 65°C for 4–12 hours.  The assembled device was removed from the fluid 
layer master and covered with ScotchTM tape (3M) to protect the layer from damage and dust 
during drilling.  Inlets for the fluid layer were drilled with a 750µm drill bit.  Flat COC substrates 
were prepared by hot pressing (Carver hot press, model 3851-0) at 175°C (Tg+50°C, where Tg is 
the glass transition temperature of COC) and used as substrates for the assembled device.  For 
hot pressing, the COC sheets were placed in between microscope glass slides supported by 
blocks of flat PDMS on the top and bottom to avoid damage to the assembly under high pressure.  
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The assembly was then heated to 175°C, maintained at that temperature for 5 minutes and then 
cooled down to 75°C.  The assembly was removed from the hot press and the COC sheets were 
removed from the glass slides.38-40  The assembled COC/PDMS device was placed on a flat COC 
sheet (2 mil, 6013 grade) as a substrate.  Figure 2.2 shows the fabrication flow for the device. 
 
2.4.  Salient features of FID-based PDMS microfluidic platforms 
Solvent Compatibility: To address the issue of solvent loss (due to absorption and 
evaporation) and incompatibility with organic solvents mentioned in section 2.2, the thickness of 
the PDMS fluid and control layers was minimized (~150µm), and solvent-impermeable top and 
bottom layers were incorporated.  In platform 1, the fluid layer was placed on a glass slide, thus 
preventing solvent evaporation through the bottom.  Crystal clear tape was applied to the top of 
the chip, providing a solvent impermeable layer over the PDMS surface.  In platform 2, the fluid 
layer was placed on a COC sheet to prevent solvent evaporation from the bottom and a COC 
sheet was bonded to the top of the chip, providing a solvent impermeable layer over the PDMS 
surface.  Additionally, in both implementations, impermeable tape was used to hermetically seal 
all inlet and outlet ports immediately after mixing.   
Reducing the thickness of the PDMS layers from several mm, typically used in 
microfluidic applications, to ~150µm limited the absorption of water, methanol, and ethanol to 
0.75%, 4.5% and 22%, respectively of the total on-chip volume of all chambers and feed lines 
while accounting for each solvent’s partitioning coefficient into PDMS.20,41  These solvent 
absorption percentages are 14 times lower than those for a ~2 mm thick PDMS chip.  Reducing 
the thickness of the PDMS layers and incorporation of solvent impermeable layers at the top and 
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bottom of the chip reduced solvent loss, thereby ensuring compatibility with solvents having low 
affinity/partitioning into PDMS and swelling ratio like methanol, ethanol, isopropanol, 
acetonitrile, and trifluoroethanol.20  These are some of the solvents that are typically used in PC 
salt screening.42-44 
Bright field imaging: Visualization was difficult with platform 1 with a gold-coated glass 
slide (prior to the Raman analysis).  Use of a COC sheet with platform 2 eliminated the 
visualization problems found with platform 1.   
Raman compatibility: The background noise was minimized by reducing the thickness of 
the PDMS material (to less than ~150 µm) and eliminating the use of glass slide as a substrate by 
using a gold-coated glass or incorporating Raman transparent materials such as COC.  Reduction 
of the thickness of PDMS and introduction of a reflective gold coating on the glass substrate in 
platform 1 helped reduce the noise from PDMS and glass, respectively.  Incorporation of the 
Raman transparent material, COC, on the top and bottom of the PDMS device in platform 2 
minimized noise from PDMS and glass, and obviated the use of gold-coated glass slides. 
Figure 2.3a shows the Raman spectra of the background from different materials 
employed on chip.  The background from PDMS and COC was not significant.  However, the 
background from glass was significant and hence, its use was subsequently avoided.  Figure 2.3b 
shows the on-chip and off-chip Raman spectra of sorbic acid and the background from the blank 
microfluidic chip for platform 1.  The background was not that significant and the signals from 
sorbic acid and chip material were clearly discernible.  Similarly, Figure 2.3c shows the Raman 
spectra for sorbic acid on-chip, taken both from the top and the bottom and off-chip, and the 
background from the blank microfluidic chip for platform 2.  The background from the chip 
material was not significant and the peaks from the sorbic acid and the chip material were clearly 
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distinguishable.   
Normally closed valve architecture: Traditionally, normally open valves which require 
positive pressure for actuation, are used for fluid routing and mixing on microfluidic 
chips.8,32,33,45  Normally open valves are more prone to leakage along the edges due to the non-
conformal contact of the valve with the channel.  With normally open valves (Figure 2.4a), 
externally applied positive pressure is required to push down or push up the control valve into 
the fluid layer to close a channel or well.  The external pressure requirement limits device 
portability and confines all on-chip testing and analyses to one place.  However, in case of 
normally closed valves (Figure 2.4b), negative pressure is applied to pull up the fluid layer into 
the control valve area in order to open a channel or well.32,33  Incorporation of normally closed 
valves as opposed to normally open valves improved solvent containment, enabling long-term 
experiments without any leakage.  Device portability allowed on-chip analysis (Raman or 
birefringence) subsequent to crystals formation.  Device portability is an advantage as valves are 
closed in the state of rest, and the pneumatic lines can be removed after the fluid routing and 
mixing. 
On-chip temperature control: After mixing by free interface diffusion, the temperature 
on-chip can be controlled externally via a Peltier heater/cooler (20/20 technologies) to induce 
crystallization in cases where no crystallization was observed from diffusive mixing of the 
components.  The temperature can be varied from 0°C to 60°C.  The Peltier heater box was 
customized to fit on the microscope stage for time-lapsed imaging and to accommodate the 
microfluidic chip inside the rectangular block of the heater box. 
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2.5.  Applications of FID-based PDMS microfluidic platforms 
2.5.1. Salt/cocrystal screening microfluidic platform 
2.5.1.1. Design, operation and validation of microfluidic platform  
The microfluidic crystallization platform discussed here (Figure 2.5 and 2.6) can be used 
for screening of different salts/cocrystals of a given pharmaceutical parent compound (PC).  The 
desired platform needs to screen many conditions while consuming minimal amounts of material 
and be compatible with external analysis methods, such as optical microscopy and Raman 
spectroscopy to allow identification of the solid form (salt or cocrystal) being formed.   
Design considerations: The microfluidic platforms were fabricated and assembled using 
multilayer soft lithography procedures as described in Section 2.3.  The microfluidic network is 
designed such that the solutions of a PC in up to four different solvents (or four different 
concentrations in the same solvent) can be mixed with up to twelve counter ion (CI) solutions in 
a combinatorial fashion, establishing 48 unique conditions.  Each condition (or “well”) requires a 
volume of only 87.5 nL of PC, so that at typical PC concentrations of 20 - 200 mg/ml, each 
condition screened consumes only 1.75 - 17.5 µg of PC.  Each “well” is comprised of an isolated 
chamber for a PC solution and an isolated chamber for a CI solution (Figure 2.5a and Figure 
2.6a).  
The dimensions of the different chambers are optimized to minimize the volume used per 
well.  The volume of the CI chamber is ~2 times smaller than the volume of the PC chamber to 
minimize dilution effects.  To maintain 1:1.2 molar ratio of the PC: CI, the concentration of the 
CI has to be increased proportionally if the ratio of chamber volumes of PC: CI is 2:1.  However, 
the solubility of CI in different solvents and the necessity to mix a certain amount of CI with the 
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PC limits further reduction of the volume of the SF chamber.  Additionally, the wells need to be 
designed such that diffusive mixing is achieved fast enough for a high-throughput application 
(i.e., in less than 30 min) and slow enough to prevent massive precipitation at the onset of 
mixing.  The required length to mix within a time t can be estimated using Fick’s law, x = 
2(Dt)½, where x is the combined length of the long side of the SF and the PC chambers and D is 
the diffusivity of the diffusing species, here approximated from the diffusivity of acetaminophen, 
a sample PC in water as 4.25×10-6 cm2/s.46  For a mixing time of 20 minutes, x is about 1 mm, so 
the total length of the CI and PC chambers in the microfluidic chip was designed to be ≈1.3 mm. 
Operation of the microfluidic chip: The chambers and various feed lines were isolated by 
valves, which are closed at rest (Figure 2.5a, 2.6a).  The normally closed valves open, when 
negative pressure is applied to the control lines using a pump (Gast DOA-P704-AA Vacuum 
Pump 1/8 HP 115 VAC).32  Four types of normally closed valves were incorporated in the 
control layer: Valves for filling the PC chambers (the sets labeled “1” and “3” in Figure 2.5c2), 
valves for filling the CI chambers (set 2), valves that enable diffusive mixing between the PC 
and CI (set 3), and valves that can speed up diffusive mixing through repeated actuation (set 4) 
via added convection, if needed.  Using a pipette, 1-2 µl droplets of the different PC solutions 
were placed over the inlets of the rows (Figure 2.5b and Figure 2.6b) and then introduced 
horizontally by actuation of valve sets 1 and 3 (Figure 2.5c1) followed by gentle suction by 
applying vacuum at the outlet of the row being filled.  After closing this valve set and thereby 
constraining the PC solutions in the PC chambers, the CI chambers were purged via the actuation 
of valve set 2, followed by gentle suction at the outlets.  Subsequently, 1-2 µl droplets of the 
different CI solutions were placed over the inlets of the columns and introduced vertically by 
actuation of valve set 2 (Figure 2.5c3) followed by gentle suction at the corresponding outlets.  
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After closing valve set 2, thereby constraining the CI solutions in their corresponding chambers, 
valve set 3 was opened for about 20 minutes to induce diffusive mixing of PC and CI solutions 
confined in adjacent chambers (Figure 2.5c4).  The mixing time can be further reduced from 20 
minutes to 5 minutes by repeated actuation of valve set 4.  After mixing, the pneumatic lines can 
be detached from the chip, thus isolating individual experiments in their respective wells. 
Visualization and data collection: Throughout the mixing period and for the following 2-
24 hours after mixing, the wells were periodically monitored visually for crystal formation on an 
automated computer controlled upright optical microscope (Leica Z16 APO) equipped with a 
macro lens (Leica 10447176), a digital camera (Leica DFC280), and a motorized X-Y stage 
(Semprex KL66).  Images of each well were captured every 15 minutes by moving the 
automated motorized stage in a sequential fashion between wells using Image Pro Plus 5.1 
(Media Cybernetics).   
Within two hours of nucleation, the crystallinity of the solid forms was verified by 
birefringence.  Raman spectroscopy (Renishaw mircoPL / Raman microscope) was used to 
analyse and identify the different solid forms.  The Raman setup (Figure 2.6) comprised an 
upright microscope (Leica DM2500M) equipped with a 785 nm (Renishaw NIR diode laser 
100mW at 785nm) excitation source.  Individual wells were centred beneath the objective using 
a 5x objective in bright field mode.  By moving to higher magnification (20x and then 50x), the 
Raman light source was focused (spot size ~5 µm) on individual crystals to obtain Raman 
spectra in the range of 300-1700 cm-1. 
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2.5.1.2. Materials and Methods 
All the PCs and their respective CIs (salt formers, SFs or cocrystal formers, CCFs) were 
obtained from Sigma Aldrich (St. Louis, MO).  Fifty mg of naproxen (PC) was dispensed in four 
vials and methanol, ethanol, isopropanol, and water were added to the respective vials until 
naproxen was completely dissolved.  The vials were sonicated (Branson 2510) to augment 
dissolution.  Next, an additional 100 µl of solvent was added to each vial, thereby ensuring that 
each naproxen solution was below its solubility in the solvent used.  The resultant naproxen 
concentrations in ethanol, methanol, isopropanol, and water were 21 mg/mL, 27 mg/mL, 
26 mg/mL, and 0.05 mg/mL, respectively.  Counter ion solutions of sodium hydroxide, 
potassium hydroxide, pyridine, and arginine were prepared in methanol and isopropanol.  The SF 
concentrations were formulated such that the CI: PC molar ratios when mixed on-chip was 1.2:1 
for the naproxen solution with the highest solubility (solubility in methanol was highest).  
The procedure for preparing ephedrine solutions and SF solutions was similar to the 
procedure described above for naproxen.  Ephedrine was dissolved in methanol at a 
concentration of 1.65 g/mL of solvent.  Six acid solutions in methanol were prepared, using 
hydrochloric, sulphuric, methane sulfonic, ethane sulfonic, nitric and phosphoric acids, such that 
the resulting molar ratio of each SF and ephedrine combination when mixed on-chip was 1.2:1.  
The procedure for preparing caffeine solutions and its CCF solutions again involved 
dissolving caffeine or CCFs in different solvents, followed by sonication.  Caffeine was 
dissolved in two different solvents, methanol and acetonitrile in excess quantities (> 60 mg/ mL), 
such that some excess solid remains at the bottom after thorough mixing via sonication.  The 
following six CCF solutions were dissolved in acetonitrile in excess quantities (> 50 mg/mL): 
2,5-dihydroxy benzoic acid; 3,5-dihydroxy benzoic acid; 2,4-dihydroxy benzoic acid; 2-hydroxy 
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benzoic acid, 4-hydroxy benzoic acid and oxalic acid.  
All solutions used on-chip were introduced by first pipetting 1-2 µl droplets at the inlet 
ports, pulling the fluid into the chip via actuation of the appropriate valve sets, and applying 
vacuum suction at the appropriate fluid outlets.  Once filled, the PC and SF solutions were mixed 
diffusively for 20 minutes as discussed earlier in Section 2.5.1.1.  After the solutions were fully 
mixed, all peripheral connections (tubing for pneumatic control) were disconnected and the chip 
inlets and outlets were sealed with crystal clear tape (Hampton Research) to prevent solvent 
evaporation.  
In the case of ephedrine and caffeine, reference Raman spectra of the salts of ephedrine 
were obtained by carrying out the salt/cocrystal screen off-chip in glass vials.  With ephedrine, 
each of the six vials was filled with 200 µl ephedrine solutions in methanol (1.65 g/mL, 10 M).  
100 µl of the following SFs prepared in methanol solutions (12 M) were added in glass vials 
containing ephedrine solution to make the final solutions 20% molar excess with respect to 
ephedrine: hydrochloric acid, sulfuric acid, methane sulfonic acid, ethane sulfonic acid, nitric 
acid, and phosphoric acid.  Similarly, in the case of caffeine, each glass vial was filled with 200 
µl of the excess caffeine solution prepared in acetonitrile and methanol respectively.  100 µl of 
the excess CCF solutions dissolved in acetonitrile were added to their respective glass vials 
containing caffeine solutions.  All the vials were sonicated (Branson 2510) to induce nucleation.  
With ephedrine, the vials were left open to atmosphere to enable complete evaporation of the 
solvent to obtain enough material for Powder X-ray diffraction and/or Raman Analysis.  With 
caffeine, post-sonication solutions were allowed to sit for 4-6 hours to observe for cocrystal 
formation via solution mediated phase transformation. 47,48  Crystals were harvested from the 
respective vials and analysed under the Raman microscope (Renishaw micro PL).  Raman 
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spectra for ephedrine, caffeine, and the respective SF and CCFs powders were also obtained as 
reference and used to identify the ephedrine salts formed on-chip in combination with the spectra 
obtained from crystals off-chip.  The Raman analysis of naproxen and ephedrine salt crystals, 
and caffeine cocrystals formed on-chip was carried out using the Raman microscope as described 
in Section 2.5.1.1.  Raman spectra of the salts of naproxen are available in the literature.41,49,50 
 
2.5.1.3. Results and Discussion 
Naproxen salt screening (Validation with platform 1): Naproxen was used as a model 
acid PC that was screened with several basic SFs.50  Naproxen was dissolved in ethanol, 
methanol, isopropanol, and water at different concentrations (see Section 2.5.1.2).  The SF 
solutions comprising sodium hydroxide (NaOH), potassium hydroxide (KOH), pyridine, or 
arginine were dissolved in methanol or isopropanol.  These solutions were prepared such that the 
molar ratio of SF to PC in the resulting combinatorial mixtures was 1.2 to 1.  Figure 2.8 shows 
an optical micrograph of a whole 48-well chip.  In some wells, crystallization started within 
seconds following mixing of adjacent PC and SF solutions.  Naproxen crystallized in 44% of the 
wells with KOH, in 56% of the wells with NaOH, in 25% of the wells with arginine, and in 50% 
of the wells with pyridine.  The enlarged views in Figure 2.8 show typical examples of the 
crystals formed for each of these salts.  Further analyses of the different solid forms are 
discussed below.   
Ephedrine salt screening (Validation with platform 2): Ephedrine was used to validate 
the chip with a basic drug and various acidic SFs.  Ephedrine has been reported to form salts 
with multiple SFs.51,52  Ephedrine, dissolved in methanol at four different concentrations (see 
Section 2.5.1.2), was mixed in a combinatorial fashion with methanol solutions of the following 
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six acids: hydrochloric, sulphuric, methane sulfonic, ethane sulfonic, nitric, and phosphoric acids 
(Figure 2.9).  Crystals were obtained in the wells of all acids, except nitric acid.  Ephedrine 
crystallized with hydrochloric acid in 25% of the wells, while it crystallized in all wells with 
sulphuric, methane sulfonic, ethane sulfonic, and phosphoric acids.  The enlarged views of 
individual wells in Figure 2.8 show typical examples of the crystals formed for each of these 
salts.   
Caffeine cocrystal screen (Validation with platform 2): Caffeine was used to validate the 
chip’s capability to screen for cocrystals with various weak acidic CCFs.  Caffeine has been 
reported to form cocrystals via solution mediated phase transformation route with many weak 
acids.47,48  Caffeine, dissolved in methanol and acetonitrile in excess concentrations (see Section 
2.5.1.2), was mixed in a combinatorial fashion with acetonitrile solutions of the following six 
weak acids: 2,5-dihydroxy benzoic acid; 3,5-dihydroxy benzoic acid; 2,4-dihydroxy benzoic 
acid; 2-hydroxy benzoic acid, 4-hydroxy benzoic acid and oxalic acid (Figure 2.9).  Crystals 
were obtained in the wells of all acids, almost instantly or within a span of 2 hours, except for 4-
hydroxy benzoic acid, where no crystals were observed until complete solvent absorption into 
PDMS.  Caffeine dissolved in acetonitrile crystallized almost instantly with (2,5)-dihydroxy 
benzoic acid, (3,5)-dihydroxy benzoic acid, (2,4)-dihydroxy benzoic acid, and over a span of 2 
hours with of 2-hydroxy benzoic acid and oxalic acid.  These observations were similar to those 
observed in off-chip experiments.  The enlarged views of individual wells in Figure 2.10 show 
typical examples of the crystals formed for each of these cocrystals.   
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On-chip Analysis: The presence of crystals as well as the size and shape of a solid form 
in a given microfluidic well can typically be determined using bright field microscopy (e.g., the 
enlarged views B1, D3, and F3 in Figure 2.8).  For some wells, however, it is unclear whether 
the solid form is crystalline or amorphous (e.g., enlarged view E2 in Figure 2.9).  Viewing the 
individual wells with crossed polarized filters typically overcomes this issue because most 
crystals exhibit birefringence (see enlarged views in Figure 2.9, 2.10).  However, microscopic 
approaches do not reveal the chemical identity of a crystal.  It is particularly important to 
determine the chemical identity of the crystals observed on-chip because crystals of the PC 
and/or the SF/CCF may form in addition to, or instead of, crystals of the intended salts.  
Analytical techniques such as IR spectroscopy, Raman spectroscopy, and X-ray analysis can be 
used for clear identification of the crystalline material formed in a crystallization experiment. 
Raman spectroscopy was used for on-chip analysis of the crystals in the different wells (Figure 
2.8, 2.9 and 2.10).   
Multiple individual crystals are located and centred in bright field mode at up to 50x 
magnification, and then, Raman spectra of these individual crystals are obtained (explained in 
detail in Section 2.5.1).  Figure 2.11 shows typical Raman spectra of four naproxen salt crystals 
imaged on chip after performing the naproxen salt screen described earlier.  The enlarged view 
of the 700 - 850 cm-1 region shows unique peaks that identify each of the salts, which compare 
well to previously reported spectra for these salts.41,49,50  Figure 2.12 shows correction of on-chip 
data for background from the empty chip with the ethane sulfonate salt of ephedrine.  Figure 2.13 
shows Raman spectra for crystals of five different ephedrine salts.  Since no literature data on 
ephedrine salts and caffeine cocrystals were available, the Raman spectra of crystals obtained on-
chip and off-chip were compared.  The enlarged view of the 725-1075 cm-1 region shows unique 
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peaks for each of the salts, and agreement between the spectra from the on-chip and off-chip 
crystals.  Figure 2.14 shows Raman spectra for crystals of five different caffeine salts.  The 575-
1075 cm-1 region shows unique peaks for each of the cocrystals and shows that the spectra from 
the on-chip and off-chip grown crystals are in agreement.  In summary, the chip was able to 
screen for the salts of a basic drug, an acidic drug, and the cocrystals of a basic drug.  The 
formed salts and cocrystals could be distinguished from each other via on-chip analysis by 
Raman spectroscopy.  
 
2.5.2.  Antisolvent screening microfluidic platform 
2.5.2.1. Design, operation and validation of microfluidic platform  
In this section, the developed microfluidic platform was used to screen polymorphs and 
crystal habit of PCs.  The influence of different parameters affecting crystal habit and 
polymorphism has also been studied. 
Design of microfluidic chip: The chip is designed such that eight PC to antisolvent ratios 
(from 1:5 to 5:1) are employed across each row to achieve variable supersaturation levels within 
the wells upon mixing.  Different volumetric ratios are obtained by varying the relative sizes of 
the PC and the antisolvent chambers.  Changing the size of the chambers, by varying the ratio of 
the length og the drug chamber (LD) to the length of the antisolvent chamber (LA), not only 
changes the final composition, but is also expected to affect the supersaturation profiles (Figure 
2.15).  The dimensions of the individual chambers were designed to optimize the time for 
diffusion (~ 20 minutes), while minimizing the PC solution’s volume (50 nL), and hence the 
amount of drug used per screen.  This platform (48 wells, 6 x 8 array) allows screening with 
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different solvents, antisolvents, and/or different concentrations of the PC in one type of solvent 
across six rows.  The degree of supersaturation was varied by varying volumetric ratios of PC 
and antisolvent  (1: 5 to 5: 1) across eight wells in each row.  The effects of several parameters 
(concentration of the PC, PC to antisolvent ratio, and solvent choice) on crystal habit and 
polymorphism was studied. 
Operation of the microfluidic chip: Filling and mixing is controlled via normally closed 
valve architecture as in the case of the salt/cocrystal screening chip.32,53  Normally closed valves 
were chosen due to their excellent well-to-well isolation, portability, and valve density.  Two sets 
of valves control the fluid movement and mixing as shown in Figure 2.15.  Valve 1 controls 
filling and routing of fluid and valve 2 controls mixing.  
Visualization and data collection: Visualization and data collection were carried out as 
described in detail in Section 2.5.1.1. 
 
2.5.2.2. Materials and Methods 
All drugs and counterions were obtained from Sigma-Aldrich and used as provided.  The 
following procedure was used for the preparation of the naproxen solutions on-chip:  100 mg of 
Naproxen was dispensed into three vials and 50 mg of naproxen was dispensed into three 
additional vials.  1.5 mL of methanol, ethanol, and isopropanol were added to their respective 
vials to make one high concentration and one low concentration solution of Naproxen in each 
solvent.  The vials were sonicated (Branson 2510) to enhance dissolution.  Indomethacin 
solutions used on-chip was prepared in the same solvents such that the final concentrations were 
20 mg/mL (high) and 10 mg/mL (low). 
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All solutions used on-chip were introduced by pipetting 1-2 µl of the PC solutions and 
antisolvent solutions at their respective inlet ports, pulling the fluids into the chip via actuation of 
the appropriate valve sets, and applying vacuum suction at the appropriate fluid outlets.  Once 
filled, the PC and antisolvent solutions were mixed diffusively for 20 minutes.  
 
2.5.2.3. Results and Discussion 
To demonstrate operation and capability of the microfluidic chip, antisolvent 
crystallization experiments were performed with PCs such as naproxen and indomethacin as 
model systems.  They PCs were chosen for their widespread use in the commercial market and 
prior literature on extensive characterization regarding polymorph structure and Raman 
spectra.49,54 
Naproxen crystal habit (Validation with platform 1):  Naproxen was chosen to study the 
influence of solvent choice and supersaturation on crystal habit due to its single polymorphic 
state. 49,50  Naproxen was screened on-chip with isopropanol, ethanol and methanol, each with 
the common antisolvent, water at 67 mg/mL and 33 mg/mL of solvent.  An optical micrograph of 
the screen is shown in Figure 2.16.  Naproxen solid forms were observed in 87% of the wells 
with crystal forms in 33% of the wells.  Variations in the PC to antisolvent volumetric ratio 
resulted in the formation of crystals with different sizes, as is evident in the case of naproxen in 
ethanol (the morphology changed from a few large crystals to many small crystals as the 
antisolvent to API ratio increased).  Additionally, an increase in both the size and number of 
crystals in wells with higher concentrations of naproxen (1st, 3rd and 5th rows as compared to 2nd, 
4th, and 6th rows) was observed.   
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The variation in size and number of crystals is due to the different levels of 
supersaturation induced, which in turn influences the nucleation and growth kinetics.11,55  High 
local concentrations of antisolvent result in high levels of local supersaturation, hence, either 
large crystals or amorphous forms (in case of very high supersaturation) are formed.  In the case 
of low levels of supersaturation, small crystals are formed.  Also, close to the mixing zone, 
where supersaturations are high due to the immediate contact of PC and antisolvent, the wells 
have a higher propensity for forming amorphous forms and farther from the mixing zone, where 
supersaturations is low, the wells have a higher propensity for nucleation and crystal formation.  
Indomethacin polymorph screen (validation with platform 2): Indomethacin was chosen 
to study the influence of solvent choice and supersaturation on polymorphism, because it is 
known to have several stable polymorphs at room temperature.54,56,57  Indomethacin at 20 mg/ml 
was screened on-chip in isopropanol, ethanol, and methanol with the common antisolvent,water.  
Solid forms were observed in 96% of the wells.  An optical micrograph of the indomethacin 
screen is shown in Figure 2.17.  All known indomethacin polymorphs in the amorphous, α, and γ 
forms were identified on-chip (Table 2.1).  Methanol solutions primarily formed amorphous 
forms at high antisolvent to PC ratios and primarily formed α polymorphs (needles) at low 
antisolvent to PC ratios.  Both the ethanol and isopropanol solutions primarily formed the γ 
polymorphs, with the exception of the ethanol solutions at a 5:1 antisolvent to API ratio, where 
an amorphous form was formed.  These crystals on-chip are shown in Figure 2.16.    
Visualization and birefringence of the crystals provided information regarding crystal 
habit and polymorphism; however, further analysis was required to confirm polymorphism.  The 
solid forms were analyzed using an external Raman microscope for polymorph identification 
(see Figure 2.18).58  In the case of indomethacin in ethanol, the α polymorph was preferentially 
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formed in regions with lower supersaturations.  In some cases, the α polymorph was formed 
away from the mixing zone and “amorphous forms” were formed around the mixing zone due to 
high levels of supersaturation near the mixing zone. 
 
2.6.  Conclusion 
This chapter described the fabrication, design, operation, and applications of microfluidic 
platforms employing free interface diffusion that are capable of screening and analysing 
pharmaceutical salts and studying the influence of various parameters on polymorphism and 
crystal habit in a high-throughput and combinatorial fashion.  The platform allows reduction of 
the amount of PC used per screen, hence increasing the number of conditions that can be 
screened using a limited amount of PC.  Screening of many conditions using minimal amount of 
PC will facilitate solid form screening in the early stages of drug development, enabling early 
identification of PCs with high propensities for success.  Reduction of the thickness of the PDMS 
layer and use of solvent impermeable capping layers minimized solvent loss through evaporation 
and absorption, thereby enabling platform compatibility with organic solvents typically used in 
pharmaceutical solid form screening.  Incorporation of valves that are closed at rest improved 
solvent containment, which is convenient for long-term (>24 hours) experiments.  Additionally, 
these valves made on-chip analysis of crystal forms convenient by improving device portability.  
The simplicity of the chip design and fabrication enables immediate application in 
pharmaceutical laboratories because their use requires readily available external peripherals, 
such as pipettes and a vacuum pump. 
43	  
	  
Salt screening platform: The platform mixes PC solutions combinatorially with SF 
solutions to create an array of 4x12 unique conditions.  The 87.5-nl wells of microfluidic chips 
are significantly smaller than the wells that are typically used in traditional robotic systems (~5-
100 µl) for pharmaceutical salt screenings.  Mixing by free interface diffusion of the PC and SF 
solutions induces high local supersaturation that enhances chances of crystallization.   
Antisolvent screening platform: This device uses a minimal amount of material (50 
nL/condition), screens 48 (6 x 8 array) unique conditions, and utilizes precise fluid control to 
incorporate FID mixing of the PC with antisolvents.  The device was validated as an efficient 
and precise tool for anaylyzing the influence of supersaturation, antisolvents, and solvents on 
polymorphism and crystal habit. 
In this chapter, free interface diffusion and antisolvent addition modes of crystallization 
were tested.  However, most of salts, cocrystals or polymorphs were difficult to crystallize and 
thus the solvent mixture had to be completely evaporated to allow for crystal formation.  In the 
next chapter, a microfluidic platform that allows evaporation of the solvent in a controlled 
fashion has been discussed in detail. 
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2.7.  Figures and Tables 
 
Figure 2.1: Flow sheet showing the fabrication procedure for microfluidic platform type 1 (a) 
version 2 and (b) version 1. 
 
 
Figure 2.2: Flow sheet showing the fabrication procedure for microfluidic platform type 2. 
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Figure 2.3: (cont. on next page) 
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Figure 2.3: (a) Raman spectra for background from chip material, (b) Raman spectra showing 
improved signal to noise ratio from platform 1 in case of sorbic acid, and (c) Raman spectra 
showing improved signal to noise ratio from platform 2 in case of sorbic acid 
 
Figure 2.4: Schematic showing operation of microfluidic valves by deflection of a thin 
membrane by (a) positive pressure in a normally open valves platform, or (b) negative pressure 
in an normally closed valves platform.  Illustration credit: Josh Tice  
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Figure 2.5: (a) Schematics of the layered design of single microfluidic crystallization well in 
Platform type 1, comprised of a fluid layer with chambers for CI and PC solutions, and a control 
layer with the pneumatic control lines and valves.  This assembly is sandwiched between an 
impermeable layer and a glass slide to provide rigidity and reduce solvent loss.  The gold 
coating on the glass slide reduces noise in on-chip analysis of the crystals with Raman 
spectroscopy.  (b) Optical micrograph of a microfluidic crystallization screening chip comprised 
of a 4x12 array of wells, filled with food dye solutions to highlight its combinatorial mixing 
capabilities.  (c) Enlarged view of a 2x2 set of wells to visualize the filling and mixing process.  
First the PC solution is introduced horizontally (valves 1 and 3 actuated) and locked up in the 
PC chambers (c1).  Then SF solutions are introduced vertically (valves 2 are actuated) and 
locked up in their respective chambers (c2).  Then the valves between adjacent PC and SF 
chambers (valves 3) are opened to allow the solutions to mix (c3).  Back-and-forth actuation of 
valves 4 can be used to speed up the slow diffusive mixing process.   
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Figure 2.6. (a) Schematic of the layered design of four crystallization wells (2 x 2 array) in 
Platform type 2, comprised of a fluid layer with chambers for CI and PC solutions, and a control 
layer with the pneumatic control lines and valves.  This assembly is sandwiched between layers 
of COC on top and bottom to minimize solvent loss and enable Raman compatibility. (b) Optical 
micrograph of a microfluidic crystallization screening chip comprised of a 4x12 array of wells, 
filled with food dye solutions to highlight its combinatorial mixing capabilities.   
 
Figure 2.7: The Raman microscope setup 
(http://www.google.com/search?sourceid=chrome&ie=UTF-8&q=renishaw+mirco+PL)  
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Figure 2.8: On-chip screen of salt solid forms of Naproxen.  Rows 1, 2, 3, and 4 are filled with 
Naproxen in ethanol, isopropanol, methanol and water, respectively.  Columns A, B, C, D, E and 
F are filled with either methanol or isopropanol solutions of the following SFs: sodium hydroxide, 
sodium hydroxide, potassium hydroxide, arginine, pyridine, and potassium hydroxide, 
respectively.  Sodium, arginine, pyridine and potassium salt crystals of Naproxen are visible in 
the enlarged views (rotated 90º clockwise with respect to the view of the whole chip). 
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Figure 2.9: On-chip screen of salt solid forms of ephedrine.  Rows 1, 2, 3 and 4 are filled with 
Ephedrine in methanol.  Columns A, B, C, D, E and F are filled with the following SFs in 
methanol: hydrochloric, sulfuric, methane sulfonic, ethane sulfonic, nitric, and phosphoric acids, 
respectively.  Brightfield and birefringence images of hydrochloride, mesylate, dihydrogen 
phosphate, bisulfate, and esylate salt crystals of ephedrine are visible in the enlarged views 
(rotated 90º clockwise with respect to the view of the whole chip). 
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Figure 2.10: On-chip screen of cocrystal solid forms of caffeine.  Rows 1, 2, 3 and 4 are filled 
with caffeine in acetonitrile.  Columns A, B, C, D, E and F are filled with the following CCFs in 
acetonitrile: 3,5-dihydroxybenzoic acid, 2,5-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, 
2-hydroxybenzoic acid, oxalic acid and 4-hydroxybenzoic acid respectively.  Brightfield and 
birefringence images of 3,5-dihydroxybenzoate, 2,5-dihydroxybenzoate, 2,4-dihydroxybenzoate, 
2-hydroxybenzoate, and oxalate cocrystals of caffeine are visible in the enlarged views. 
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Figure 2.11:  On-chip analysis of various naproxen salt crystals using Raman spectroscopy.  
Magnified views of the 700 - 850 cm-1 range are provided to highlight the spectral differences 
between the different salts. 
 
Figure 2.12:  On-chip analysis of ethane sulfonate salt of ephedrine. Correcting the on-chip 
data for background due to signal from the material used in the microfluidic chip. 
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Figure 2.13: Analysis of five ephedrine salts formed on-chip (solid lines) and off-chip (dashed 
lines) using Raman spectroscopy.  Magnified views of the 725 - 1075 cm-1 range are provided to 
highlight the spectral differences between the different salts. 
 
 
Figure 2.14: Analysis of five cocrystals of caffeine and caffeine formed on-chip (solid lines) and 
off-chip (dashed lines) using Raman spectroscopy.  Magnified views of the 575 - 1175 cm-1 
range are provided to highlight the spectral differences between the different salts. 
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Figure 2.15: (a) A schematic depiction of the design of the microfluidic chip for antisolvent 
screening.  All fluids are contained in the fluid layer, including both the half wells for the drug 
(blue) and the antisolvent (yellow).  Unique solvents are used in each row.  Varying LD:LA 
(volume of the drug solution to antisolvent), across the chip controls the ratio of the antisolvent 
to the drug.  The fluid routing and mixing is controlled via valve actuation via vacuum control.  
Valve 1 controls the filling and valve 2 controls the mixing between the drug and the antisolvent. 
(b) Optical micrograph of a microfluidic crystallization screening chip comprised of a 6x8 array 
of wells, filled with food dye solutions to highlight its combinatorial mixing capabilities.  (b1) 
Magnified view of the optical micrograph, after filling of food dye solutions via actuation of Valve 
1, before mixing.  (b2) Magnified view of the optical micrograph, after mixing of food dye 
solutions via actuation of valve 2. 
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Figure 2.16: Optical Micrograph of the microfluidic chip filled with Naproxen in 3 solvents at two 
concentrations mixed with the antisolvent, water.  The 1st, 3rd, and 5th rows have high 
concentrations of Naproxen in methanol, ethanol, and isopropanol respectively.  The 2nd, 4th, 
and 6th rows have low concentrations of Naproxen in methanol, ethanol, and isopropanol 
respectively.  The crystal habit varied based on the solvents, concentrations of API and API to 
antisolvent ratios.  The image on the right shows various Naproxen crystals grown on-chip. 
 
Figure 2.17:  Optical Micrograph of microfluidic chip filled with Indomethacin in 3 solvents mixed 
with the antisolvent, water.  The 1st and 2nd rows are filled with Indomethacin in methanol, the 3rd 
and 4th rows are filled with Indomethacin in ethanol, the 5th row and 6th rows are filled with 
Indomethacin in isopropanol.  The polymorphism generated was found to depend on the 
solvents and the API to antisolvent ratios.  The image on the right shows optical micrographs of 
various Indomethacin crystals grown on-chip. 
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Figure 2.18: Two regions of Raman spectra of the α, γ, and amorphous polymorphic forms of 
Indomethacin on-chip along with zoomed in views of the polymorphic forms.  Raman spectra 
are offset for comparison purposes.  
 
Table 2.1:  Polymorphic data for the Indomethacin crystals identified on-chip.  α, γ, and a 
represent the α, and γ polymorphs as well as the amorphous state. 
Solvent / 
Concentration 
Volumetric Ratio API: Counterion  
1:5 1.6:4.4 2.1:3.9 2.7:3.3 3.3:2.7 3.9:2.1 4:4:1.6 5:1 
MeOH / High a a a a a α α a 
MeOH / Low a a a a α α α α 
EtOH / High a/γ γ γ γ γ γ γ γ 
EtOH / Low a/ γ γ γ γ γ γ γ γ 
IPA/low γ γ γ - - - -  -  
IPA/High γ γ γ γ γ γ γ γ 
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Chapter 3 
EVAPORATION-BASED MICROFLUIDIC PLATFORMS FOR SOLID FORM 
SCREENING OF PHARMACEUTICAL PARENT COMPOUNDS 
3.1.  Introduction 
3.1.1.  Motivation 
In pharmaceutical crystallization, evaporation of the solvent mixture is used to screen for 
solid forms when methods like reactive crystallization, antisolvent addition, temperature control, 
and slurry conversion fail to give crystalline solid forms.1-5  During evaporation of the solvent, 
concentrations of the pharmaceutical parent compound (PC) and the counter ion (CI) increase, 
and the pharmaceutical salt or cocrystal form either crystallizes out, or precipitates as an 
amorphous solid when the solubility boundary is crossed.6  With bench-top experiments, limited 
control over the evaporation rate of solvents typically used for pharmaceutical crystallization 
(e.g., water, methanol, ethanol, acetonitrile), results in uncontrolled and inconsistent evaporation 
rate making it challenging to obtain crystalline material.  Controlling the evaporation rate enables 
screening of different rates of supersaturation and guarantees phase transition, increasing chances 
of successful crystallization screen.6,7  A PDMS-based evaporation platform has been reported 
where control over evaporation rates was achieved by changing channel dimensions.6  In that 
study, a systematic procedure for protein crystallization was developed to identify crystal 
producing conditions as a function of protein and precipitant concentrations and time.6  PDMS is 
permeable to several solvents, which results in considerable variability in evaporation rates.  To 
address this issue, a high-throughput polypropylene platform was developed that gave consistent 
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evaporation rates and enabled simultaneous screening of multiple conditions.7  This platform was 
used to study the effect of initial protein concentration and evaporation rate on the type of crystal 
formed.  Additionally, phase diagrams for soluble and membrane protein systems were 
reported.7,8 
In this Chapter, the development of a high-throughput microfluidic platform employing 
evaporation channels to control the rate of evaporation is described.  Reduction in the thickness 
of PDMS layers and incorporation of impermeable materials aids in minimizing solvent 
permeation through PDMS, minimizing variability in evaporation rates.  Solutions of PCs and 
CIs were prepared in solvents typically used in the pharmaceutical industry (e.g., ethanol, 
methanol, acetonitrile).  The solutions were mixed via free interface diffusion, and subsequently 
the solvent was evaporated through evaporation channels in a controlled manner.  These 
platforms employ sub-microliter volumes of PC solutions, which is an order of magnitude lesser 
than the volumes utilized in typical bench-top experiments.  These platforms would enable solid 
form screening earlier in the drug development process when only limited quantities of PC are 
available, facilitating better selection for drugs with higher probabilities of success.  In the 
following Sections we discuss, (a) design, fabrication, and operation of the evaporation-based 
microfluidic platform, and (b) validation of the platform for screening crystallization conditions 
for salts and cocrystals of different PCs. 
 
3.1.2.  Concept of controlled evaporation 
A droplet containing a mixture of the PC and CI (salt former (SF) or cocrystal former 
(CCF)) is placed in a reservoir that is connected to the external environment by a channel of 
length L and area Ac, as shown in Figure 3.1a.6  Figure 3.1b shows the high throughput 
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polypropylene platform developed by Talreja et al.7,8  Since the external environment is typically 
dry, a driving force is established for evaporation of the solvent within the drop until the mixture 
is completely dry.   
Assuming that the major resistance to mass transfer occurs in the capillary channel, the 
rate of volumetric loss of the solvent (at steady state) can be expressed by the equation9 
! = !  (∆!) !!!     (1) 
where, K is the overall mass transfer coefficient, ΔP is the pressure difference between the vapor 
phase around the drop and the external environment, A is the cross-Sectional area of the diffusion 
channel, and L is the length of the diffusion channel.  The overall mass transfer coefficient K is ! = !"!"!  (2) 
where, D is the diffusivity of the solvent vapor in air, R is the universal gas constant, M is the 
molecular weight of solvent, ρ is the solvent density and T is the temperature.  K can also be 
determined experimentally.  The value of K will depend on the type of the solvent being 
evaporated.  As the PC and CI concentrations tend to be low, the vapor pressure around the drop 
is only a weak function of the precipitant and protein or PC concentrations until drying is nearly 
complete.  As a result ΔP can be assumed to be nearly constant provided that the vapor pressure 
in the external environment does not change dramatically.  Therefore, J is nearly constant 
throughout the course of an evaporation experiment and only depends on the geometric Ac/L 
ratio (refer to Equation 1). 
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3.1.3. Selection of solvent resistant material for evaporation layer fabrication 
Thiolene optical adhesives were explored as the material of choice for fabrication of the 
evaporation channel layer, which controls the rate of solvent evaporation.  Thiolene was chosen 
due to the following reasons: (a) it is resistant to both polar as well as many non-polar solvents 
(e.g., toluene, benzene)10, (b) it is impermeable to air and water-vapor unlike PDMS, (c) it 
enables replication of sub-micron features, as well as features with large aspect ratios due to its 
higher elastic modulus as compared to PDMS, and (d) it is optically translucent enabling 
imaging and microscopy.11  Among the various formulations of thiolene-based optical adhesives 
available (NOA 61, 68, 81, Norland Products), NOA 81 is most commonly used as it cures 
quicker than other adhesives.11-15  Thiolene-based optical adhesives have been used to assemble 
micro-patterned stickers by UV-curing of liquid thiolene sandwiched between a PDMS mold and 
a flat PDMS layer.  As PDMS is oxygen permeable, a thin layer of thiolene close to the PDMS 
surface remains uncured, and hence, post-UV exposure, the thiolene sticker has adhesive 
properties on both the surfaces.  This enabled stacking of multiple thiolene molds or bonding to a 
glass substrate using either surfaces.  The stacked layers were further cured under UV to bond 
the layers.11  Thiolene devices were also prepared by spin coating thiolene on a PDMS mold, 
followed by curing under UV exposure, and subsequent bonding of the partially uncured side of 
thiolene to a glass substrate by UV exposure.12  The adhesive nature of PDMS-contacting surface 
of thiolene has also been exploited to glue thin layers of thiolene between different substrates 
(e.g., glass, PMMA, SU-8).15  Multilayer thiolene microfluidic chips have also been developed 
by rapid prototyping via photo-polymerization and transfer lamination employing polyethylene 
(PE) sheets and transparency masks.  PE sheets were used as interface layers between masks and 
liquid thiolene, and the masks used for selective polymerization resulting in patterned surfaces.16  
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Due to its solvent-resistance, imperviousness, and ease of fabrication, thiolene was chosen as the 
material for fabricating the evaporation channel layer. 
 
3.2. Fabrication of the evaporation-based microfluidic platform 
The hybrid microfluidic chips consist of a COC backing layer, thin PDMS control and 
fluid layers, a COC substrate spin-coated with a thin layer of PDMS, and a thiolene evaporation 
channel layer.  The masters for the control and the fluid layers were prepared as described in 
Chapter 2, Section 2.3.1.  The fluid layer (75 µm) and the control layer (85 µm) were prepared 
by spin coating 15:1 PDMS on the fluid layer master at 1300 rpm and 5:1 PDMS on the control 
layer master at 1100 rpm.  The two layers were partially cured by heating at 65°C for 
approximately 30 minutes.  2mil COC film was bonded irreversibly on top of the control layer 
mold by treatment with oxygen plasma as described in Section 2.3.3.  The control layer mold 
bonded to the COC sheet was then removed from the control layer master, inlets holes were 
drilled and the control layer mold was manually aligned over the fluid layer.  The assembled 
device was heated at 65°C to allow for complete curing of PDMS, removed from the fluid layer 
master and the inlets holes were drilled as explained in Section 2.3.3. 
The interface layer between the assembled COC/PDMS device and the evaporation layer 
(thiolene) is comprised of a COC sheet (2mil, 6013 grade) and a very thin layer (~ 20 µm) of 
PDMS.  The PDMS layer allowed for reversible bonding of the interface layer with thiolene 
(NOA 81, Norland products, Cranbury, NJ).  The interface layer was prepared by spin coating 
5:1 PDMS at 3000 rpm on a blank silicon wafer evaporated with a silane monolayer.  The PDMS 
layer was partially cured at 65°C for 30 minutes and then the COC sheet was irreversibly bonded 
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on top of the PDMS layer following the procedure explained for preparation of the control layer 
in Section 2.3.3.  Holes connecting the assembled COC/PDMS device and the thiolene 
evaporation channels were drilled with a 750 µm drill bit in a Dremel drill.   
The thiolene layer comprising the microchannels permitted control over the rate of 
solvent evaporation.  Thiolene mold was prepared as described in previous work with some 
modifications.11  To prepare the thiolene molds, a 4” silicon master was patterned with 15 µm 
tall features using positive photoresist SPR 220-7 (Rohm and Haas Electronic Materials).  This 
photoresist layer (being plasma resistant) acts as a sacrificial layer while dry etching of the 
silicon wafer.  Microchannels were etched in the wafer using deep reactive ion etching (DRIE) 
(PlasmaTherm ICP-DRIE etching system).  The SPR 220-7 layer was then washed off with 
acetone and the feature heights were confirmed by profilometry (Profilometer - KLA Alphastep 
IQ). The etched wafer was then silanized for 4 hours.  The etched features were transferred onto 
a PDMS mold by pouring 5:1 PDMS on the etched silicon wafer and cured by heating at 65°C 
for approximately 1 - 2 hours.  The PDMS mold was removed from the etched silicon wafer.  A 
3” x 2” PDMS window frame (5:1 PDMS), 2 mm in height was reversibly sealed on the side of 
the PDMS mold with embossed features to define the dimensions of the thiolene mold.  Liquid 
thiolene was pipetted onto the PDMS mold, avoiding bubbles.  A microscope slide was contacted 
on top of the PDMS window, such that it facilitated a flat and rigid thiolene layer.  Thiolene was 
then cured by UV exposure (Flood exposure) for around 6-10 minutes on one side, and then 
flipped and exposed again for another 6-10 minutes.12  The thiolene mold was then removed 
from the PDMS mold.  Figure 3.2 illustrates the fabrication flow for the evaporation device.  
Figure 3.3a illustrates the fabrication flow for the thiolene mold and Figure 3.3b shows the 
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optical micrographs of a cross Section of the evaporation channel layer in Figure 3.3b1 DRIE 
etched silicon wafer, Figure 3.3b2 PDMS mold, and Figure 3.3b3 thiolene mold.  
The final device was assembled such that the interface layer with drilled holes was in 
contact with the thiolene mold.  The assembled COC/PDMS/PDMS device and the interface 
layer were placed in contact such that the holes in the interface layer were aligned with the 
centers of the evaporation chambers in the PDMS fluid layer.  Figure 3.4a shows the layer-by-
layer assembly of the device. 
 
3.3. Salient features of the evaporation-based microfluidic platform 
Solvent compatibility: Reduction in the thickness of the PDMS material (~150µm), 
incorporation of solvent-impermeable top (COC) and bottom layers (COC/PDMS), and 
incorporation of solvent resistant and impermeable thiolene evaporation channel layer ensures 
compatibility with solvents typically used in the pharmaceutical industry.  Detailed description 
has been provided in Section 2.4. 
Bright field imaging: Incorporation of optically transparent materials (COC, PDMS, and 
thiolene11) improved visualization and imaging.  The issue of background birefringence due to 
thiolene was handled by peeling off the COC/PDMS/PDMS/COC assembly at the end of the 
experiment before visualization with a cross-polarizer. 
Raman compatibility: For Raman analysis, at the end of an evaporation experiment, the 
COC/PDMS/PDMS/COC layer is removed from the thiolene layer and the thin PDMS layer at 
the bottom of the COC layer is peeled off.  The device being analyzed by Raman spectroscopy 
therefore has the same layer arrangement as in the case of platform 2 described in Chapter 2.  
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This set-up provides minimum background (explained in Section 2.4), enabling clear 
identification of salts or cocrystals formed on-chip.  
Controlled evaporation: (a) Incorporation of solvent resistant and impermeable thiolene 
evaporation channels at the bottom, and (b) reduction in the thickness of PDMS and (c) 
incorporation of impermeable layers restricts the solvent loss due to permeation of solvent vapor 
through the chip material, and hence, minimizes the variability in the evaporation rates.  
 
3.4. Design, operation and validation of evaporation-based microfluidic 
platform 
3.4.1. Design of the microfluidic platform  
The microfluidic platforms were fabricated and assembled using multilayer soft 
lithography procedures as described in Section 3.2.  The microfluidic network is designed such 
that the solution of a PC in one solvent (with four different evaporation rates) can be mixed with 
up to six counter ion (CI) solutions in a combinatorial fashion, resulting in 24 unique conditions.  
Each condition (or well) requires a volume of only 200 nL of PC, so that at typical PC 
concentrations of 5–50 mg/ml, each condition screened consumes only 1-10 µg of PC.  Each 
well is comprised of an isolated chamber for a PC solution, an isolated chamber for a CI solution 
and an isolated chamber that connects the mixed solution to the ambient conditions regulating 
solvent evaporation (Figure 3.4a).  The dimensions of different chambers were such that the 
volume ratios of PC: CI chambers were ~ 2:1.  This ratio could not be increased further due to 
the limited solubility of CI in the solvent and the requirement for maintaining a 1:1.2 molar ratio 
of PC:CI.  The sizes of the wells were 2.25 times more than the well sizes in case of the FID-
67	  
	  
based microfluidic chips to allow for sufficient quantity of the PC (as low concentrations of PC 
are used) in each well.  The wells were designed such that diffusive mixing is fast enough (i.e., in 
less than 30 min) for high-throughput applications, and slow enough to prevent massive 
precipitation at the onset of mixing.  The required length to mix within a time t was estimated 
using Fick’s law, x = 2(Dt)½, where x is the combined length of the long side of the SF and the 
PC chambers and D is the diffusivity of the diffusing species, and was found to be approximately 
1.6 mm for a mixing time of ~ 30 minutes.  Therefore, the combined length of the CI and PC 
chambers was kept as 1.6 mm. 
Evaporation channels: From our previous work on evaporation-based crystallization7, the 
rate of solvent evaporation was found to be purely a function of the evaporation channel 
dimensions, if the permeability of solvent vapor through the materials used for chip fabrication 
was restricted.  Specifically, the evaporation rate depends on the cross-Sectional area (Ac) and 
the length (L) of the evaporation channel (Eq. 1).  In our previous work6,7, where each well had 
an aqueous solution, for a rate of evaporation (J) at 0.042 µl/hr required an evaporation channel 
with a circular cross-Section of 0.6 mm (Ac = 0.3 mm2) and length of 5 mm, resulting in an Ac/L 
ratio of 60 µm.  Table 3.1 shows the dimensions of the evaporation channels used to induce three 
different rates of evaporation on chip (complete evaporation in 10, 25, and 50 hours).  The last 
row had no evaporation channels and was treated as a control for the absorption/evaporation of 
the solvent through the COC/PDMS/PDMS assembly.  The depth of the microchannels was 
200µm (Ac= 200 µm x w, where w is the width of the channel in µm).  The other dimensions are 
shown in Table 3.1.   
Modular design: The modular design of the platform is shown in figure 3.5.  At the end 
of an evaporation experiment, the COC/PDMS/PDMS/COC assembly can be removed from the 
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thiolene mold for subsequent on-chip analysis by Raman spectroscopy and birefringence 
analysis.  The COC/PDMS/PDMS/COC assembly is similar to the one developed in Chapter 2, 
and is compatible with Raman analysis and birefringence. 
 
3.4.2. Operation of the microfluidic platform 
The chambers and various feed lines were isolated by normally closed valves, which 
were actuated by applying negative pressure.  Five types of normally closed valves were 
incorporated in the control layer: valves for filling the PC chambers (the sets labeled “1” and “3” 
in Figure 3.4c2), valves for filling the CI chambers (set 2), valves that enable diffusive mixing 
between the PC and CI (set 3), valves that if needed can speed up the diffusive mixing through 
repeated actuation (set 4) via added convection, and valves that enable transfer of mixed solution 
into the evaporation chamber (set 5).  Using a pipette, 1-2 µl droplets of the different PC 
solutions were placed over the row inlets (Figure 3.4b) and introduced horizontally by actuation 
of valve sets 1 and 3 (Figure 3.4c1) followed by suction (by applying vacuum) at the outlet of the 
corresponding row.  After closing this valve set, and thereby constraining the PC solutions in the 
PC chambers, the CI chambers were purged via actuation of valve set 2, followed by gentle 
suction at the outlets.  Subsequently, 1-2 µl droplets of the different CI solutions were placed 
over the columns inlets and introduced vertically by actuation of valve set 2 (Figure 3.4c2) 
followed by suction (via vacuum) at the corresponding outlets.  After closing valve set 2, thereby 
constraining the CI solutions in their corresponding chambers, diffusional mixing of 
combinations of PC and CI solutions confined in adjacent chambers was induced by opening 
valve set 3 for about 30 minutes (Figure 3.4c3).  After complete mixing, the mixed solutions 
were then transferred to the evaporation chamber via actuation of valve set 5 and hence, 
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connected to the evaporation channels (Figure 3.4c4).  Mixed solutions were pushed in to the 
evaporation chamber via positive pressure application at the inlets of valve set 4.  Valve set 5 
was kept actuated throughout the duration of the experiment to allow for complete evaporation of 
the solvent in the PC chamber and that transferred into the evaporation chamber.  All the other 
pneumatic lines were detached from the chip because all valves are closed when not actuated. 
Visualization and data collection: Throughout the evaporation period (10-50 hours), the 
wells were periodically monitored for solid formation on an automated computer controlled 
imaging upright optical microscope (Leica Z16 APO) equipped with a macro lens (Leica 
10447176), a digital camera (Leica DFC280), and a motorized X-Y stage (Semprex KL66).  
Images of each well were acquired every 15-20 minutes by moving the automated motorized 
stage in a sequential fashion between wells using Image Pro Plus 5.1 (Media Cybernetics).  At 
the end of the evaporation experiment, the volume of the droplets inside the microfluidic well 
was traced as a function of time in Image J, to compute the rate of evaporation of the droplet 
inside each microfluidic well. 
After complete evaporation of the solvent, the crystalline nature of the solid forms 
crystallized on-chip was verified by birefringence.  Raman spectroscopy (Renishaw mircoPL / 
Raman microscope) was used to analyse and identify the different solid forms.  The Raman setup 
is comprised of an upright microscope (Leica DM2500M) equipped with a 785 nm (Renishaw 
NIR diode laser 100mW at 785nm) excitation source.  Using a 5x objective in bright field mode, 
individual wells were centred under the objective.  By moving to higher magnification (20x and 
then 50x), the Raman light source was focused (spot size ~5 µm) on individual crystals to obtain 
Raman spectra in the range of 300 - 1700 cm-1. 
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3.4.3. Validation of the microfluidic platform: salt/cocrystal screening 
3.4.3.1. Materials and Methods 
All the PCs and their respective counter ions, CIs (salt formers, SFs or cocrystal formers, 
CCFs) were obtained from Sigma Aldrich (St. Louis, MO).  120 mM tamoxifen (PC) was 
prepared in a glass vial containing ethanol.  The vial was sonicated (Branson 2510) to augment 
dissolution.  250 mM salt former (SF) solutions of benzoic acid, citric acid, fumaric acid, 
methane sulphonic acid, succinic acid, and tartaric acid were prepared in ethanol to maintain ~ 
1.2:1 molar ratio of CCF: PC. 
The procedure for preparing theophylline solutions and its CCF solutions was similar to 
the procedure described above for tamoxifen.  Theophylline was dissolved in 1:1 ethanol:water 
at a concentration of 0.1 M.  Four acid solutions in 1:1 ethanol:water were prepared using 
glycolic acid, 2,5-dihydroxy benzoic acid, 4-hydroxy benzoic acid, and sorbic acid such that the 
resulting molar ratio of each CCF and theophylline combination when mixed on-chip was 1.2:1.   
Once filled, the PC and CI solutions were mixed diffusively for 30 minutes as discussed 
earlier in Section 3.4.2.  After the solutions were fully mixed, the solutions were connected to the 
evaporation chambers for the entire duration of the experiment to allow for complete evaporation 
of the solvent.  The chip inlets and outlets were sealed with Crystal Clear TapeTM (Hampton 
Research) to prevent solvent evaporation at the inlets.  
Reference Raman spectra of salts of tamoxifen and the cocrystals of theophylline were 
obtained by carrying out the salt/cocrystal screen off-chip in glass vials (bench top) to verify the 
identity of the solid form crystallized on-chip.  With tamoxifen, each of the six vials was filled 
with 200 µl tamoxifen solutions in ethanol (120mM).  100 µl of the following SF solutions 
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prepared in ethanol (250 mM) were added to glass vials containing tamoxifen solution: benzoic 
acid, citric acid, fumaric acid, methane sulphonic acid, succinic acid, and tartaric acid.  Similarly, 
in the case of theophylline, each glass vial was filled with 200 µl of 0.1 M theophylline solution 
prepared in 1:1 ethanol:water.  100 µl of the following CCF solutions (0.2 M) dissolved in 1:1 
ethanol:water were added to their respective glass vials containing theophylline solutions: 
glycolic acid, 2,5- dihydroxy benzoic acid, 4-hydroxy benzoic acid, and sorbic acid.  All of the 
vials were sonicated (Branson 2510) and subsequently left open to atmosphere to enable 
complete evaporation of the solvent in order to obtain enough material for powder X-ray 
diffraction and/or Raman Analysis.  Crystals were harvested from the respective vials and 
analyzed under the Raman microscope (Renishawn micro PL). Raman spectra of tamoxifen, 
theophylline, and respective SF and CCFs powders were also obtained as reference.  The Raman 
spectra obtained were used to identify the tamoxifen salts and theophylline cocrystals formed on-
chip in combination with spectra obtained from crystals off-chip.  The on-chip Raman analysis 
was carried out using the Raman spectroscopy as described in Section 3.4.2.   
 
3.4.3.2. Results and Discussion 
Evaporation rates: The 24-well chip was tested to study the rates of evaporation (3 
different rates) and absorption of different solvents (methanol, ethanol, and water) on-chip.  The 
Evaporation rates were computed by tracing the volume of the droplet inside each microfluidic 
well in Image J.  Figure 3.6 shows a plot of time-lapsed evaporation of the solvent with Ac/L as 
the varying parameter.  The order of the evaporation rates for different solvents was as expected: 
methanol>ethanol>water.  
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Tamoxifen salt screening: Tamoxifen was used as a model acid PC that was screened 
with several basic SFs.17  Tamoxifen and its SF solutions were prepared in ethanol as explained 
in Section 3.4.3.1.  These solutions were prepared such that the molar ratio of SF to PC in the 
resulting combinatorial mixtures was 1.2:1.  Figure 3.7a shows an optical micrograph of a 24-
well chip that has been removed from the thiolene mold.  As the solution evaporated at different 
rates, crystal formation was observed in almost all the wells, except for benzoate, succinate, and 
methane sulphonate salts where gel formation or amorphous solid forms were occasionally 
observed in case of high rates of evaporation.  Similar behaviour was observed when the 
crystallization was carried out in bench-top experiments.  The enlarged views in Figure 3.7b 
shows typical examples of crystals formed for each of these salts.  Visualization of the solid 
forms was carried out under a cross polarizer (birefringence) to confirm the presence of 
crystalline material (Figure 3.7c) which confirmed the crystalline nature in the case of methane 
sulphonate, succinate, fumarate, and tartarate salt forms.   
Theophylline salt screening: Theophylline was used to validate the chip with a basic drug 
and various acidic CCFs.  Theophylline has been reported to form cocrystals with multiple 
CCFs.18-20 Theophylline, dissolved in 1:1 ethanol: water, was mixed in a combinatorial fashion 
with 1:1 ethanol: water solutions of its CCFs as explained in Section 3.4.3.2.  Figure 3.8a shows 
an optical micrograph of the 24well chip, which has been removed from the thiolene layer.  
Crystals were obtained in almost all the wells, however, in case of high evaporation rates 
amorphous forms or gel formation was observed in some of the wells.  The enlarged views of 
individual wells in Figure 3.8b show typical examples of crystals formed for each of these salts.  
Visualization of the solid forms under a cross polarizer helped in confirming the presence of 
crystalline material as opposed to amorphous forms or gels (Figure 3.8c).   
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However, microscopic approaches do not reveal the chemical identity of a crystal.  It is 
particularly important to determine the chemical identity of crystals observed on-chip because 
crystals of the PC and/or the SF/CCF may form in addition to, or instead of, crystals of the 
intended salts/cocrystals.  To confirm the identity of the solid form crystallized on-chip, a 
spectroscopic analysis technique (Raman spectroscopy) was used (Figure 3.9 and Figure 3.11).   
On-chip Raman Analysis: Multiple individual crystals are located and centered in bright 
field mode at up to 50x magnification, and then, Raman spectra of these individual crystals were 
obtained (explained in detail in Section 3.4.2).  Since no literature data on tamoxifen salts and 
theophylline cocrystals were available, the Raman spectra of crystals obtained on-chip and off-
chip were compared.  Figure 3.9 shows typical Raman spectra of six tamoxifen salt crystals 
imaged on chip after performing the evaporative crystallization screen with tamoxifen described 
earlier. The enlarged view of the 930-1530 cm-1 region shows unique peaks that identify each of 
the salts.  All the Raman spectra compare very well with the Raman spectra for crystals formed 
off-chip.  Figure 3.10 shows the detailed Raman spectra for tamoxifen benzoate.  Raman 
spectrum of tamoxifen benzoate crystallized on-chip was compared with Raman spectra of the 
following: tamoxifen benzoate crystallized off-chip, free tamoxifen, free benzoic acid, and empty 
chip in order to confirm the chemical identity of the crystal.  Figure 3.11 shows Raman spectra 
for crystals of four different theophylline cocrystals. The Raman spectrum for the sorbate 
cocrystal was not included in the analysis, as it did not compare well with the Raman spectrum 
for crystals obtained off-chip. The enlarged view of the 750-1150 cm-1 region shows unique 
peaks for each of these salts and agreement between the spectra from the on-chip and off-chip 
grown crystals, with the exception of the 4-hydroxy benzoate cocrystal.  
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In summary, the chip was able to screen for salts as well as cocrystals.  The formed salts 
and cocrystals could be distinguished from each other via on-chip analysis using Raman 
spectroscopy.  
 
3.5.  Conclusion 
This Chapter described the fabrication, design, operation, and application of the 
evaporation-based microfluidic platform.  The platform was successfully used to screen for salts 
and/or cocrystals of different PCs.  The platform allowed for reduction in the amount of PC used 
per screen, which allows for multiple conditions to be screened with limited amount of PC.  
Screening of multiple conditions with limited PC would facilitate screening in the early stages of 
drug development, and therefore, allow for better selection of PCs with propensity for success.  
The platform was compatible with a wide variety of organic solvents typically used in the 
pharmaceutical industry.  The modular design of the platform enables compatibility with on-chip 
Raman analysis.  The microfluidic platform developed has immediate application in the 
pharmaceutical industry, as the platform requires cheap and readily available external 
peripherals, such as pipettes and a vacuum source.  
The PDMS-based microfluidic platforms as described in Chapters 2 and 3, find 
applications in the pharmaceutical industry due to their compatibility with various polar solvents 
and Raman analysis.  However, its incompatibility with other organic solvents (e.g., 
tetrahydrofuran, hexane, dimethylsulfoxide) that are used in the pharmaceutical industry, limits 
their use with specific polar solvents.  Additionally, PDMS being a hydrophobic material has a 
tendency to absorb hydrophobic molecules21,22, so absorption of PCs (hydrophobic in nature) 
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into PDMS is inevitable.  However, in case of platforms described in Chapters 2 and 3, the 
absorption should be minimal due to reduction in thickness of the PDMS layers.  Due to 
incompatibility with non-polar organic solvents and absorption of PCs into PDMS, the 
development of microfluidic platforms employing solvent-resistant materials is critical.  In the 
next Chapter, efforts in developing a microfluidic platform employing solvent resistant materials 
will be discussed.  
 
3.6. Figures and Tables 
 
 
Figure 3.1: (a) Design of the evaporation channel for crystallization of the droplet. (b) Optical 
Micrographs of multi-compartment evaporation platform in polypropylene. For visualization 
purposes, the liquid drops are dyed blue. The end of all evaporation channels can be seen in 
the side face of the device. (Figure adapted from Talreja et al. 20056) 
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Figure 3.2: Flow sheet showing the fabrication procedure for microfluidic platform.  Fabrication 
procedure for thiolene is shown in Figure 3.3.  
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Figure 3.3: (a) Flow sheet showing the fabrication procedure for thiolene mold.  (b) Optical 
micrograph showing a cross Section of the evaporation channels in (b1) etched DRIE silicon 
wafer, (b2) PDMS mold, and (b3) thiolene mold.  
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Figure 3.4: (a) Schematics of the layered design of four microfluidic crystallization wells. The 
platform comprises a PDMS fluid layer and control layer, sandwiched between a COC layer on 
top to reduce solvent loss and one at bottom to allow for Raman compatibility.  The bottom COC 
layer is spin coated with a thin layer of PDMS and an additional layer comprised of thiolene is 
employed to allow for complete evaporation of the solvent in a controlled fashion.  The fluid 
layer has chambers for PC, counterion solutions, and the transferred mixed solution and the 
control layer has valves 1 – 5 for fluid routing, mixing and transfer into the evaporation chamber.  
(b) Optical micrograph of evaporation based microfluidic crystallization screening chip 
comprised of a 4 x 6 wells array, filled with food dye solutions.  (c) Enlarged view of a 2 x 2 set 
of wells to visualize the filling, mixing and transfer process.  PC solutions are filled horizontally 
(valves 1 and 3 actuated via vacuum) (c1).  Counterion solutions are filled vertically (valves 2) 
(c2). Solutions are mixed (valves 3) (c3). Mixed solutions are transferred into the evaporation 
chamber (valves 5) (c4). Applying positive pressure to valves 4 assists in transfer of mixed 
solutions.  The transferred solution is then evaporated through the evaporation channels. 
 
 
Figure 3.5: Modular design: top layer is the COC/PDMS/PDMS/COC layer filled with food dye 
solutions to demonstrate combinatorial mixing, bottom layer is the thiolene mold on glass. At the 
end of the experiment, the top layer can be removed from the bottom layer for subsequent on-
chip analysis. 
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Figure 3.6: Graph showing the time lapsed evaporation of different solvents with Ac/L as a 
parameter. 
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Figure 3.7: (a) On-chip screen of salt solid forms of tamoxifen.  Rows 1, 2, 3 and 4 are filled 
with tamoxifen in ethanol.  The rate of evaporation of solvent is increased from top to bottom.  
Columns A, B, C, D, E and F are filled with the following SFs in ethanol: benzoic, citric, fumaric, 
methane sulfonic, succinic, and tartaric acids, respectively.  (b) Brightfield images and (c) 
images under a cross-polarizer of benzoate, citrate, fumarate, mesylate, succinate and tartarate 
salt crystals of ephedrine are visible in the enlarged views. 
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Figure 3.8: (a) On-chip screen of cocrystal solid forms of theophylline.  Rows 1, 2, 3 and 4 are 
filled with theophylline in 1:1 ethanol: water.  The rate of evaporation of solvent is increased 
from bottom to top.  Columns A, B, C, and D are filled with the following CCFs in 1:1 
ethanol:water: glycolic acid , 2,5-dihydroxybenzoic acid, 4-hydroxybenzoic acid, and sorbic acid 
respectively.  (b) Brightfield images and (c) images under a cross-polarizer of glycolate, 2,5-
dihydroxybenzoate, 4-hydroxybenzoate, and sorbate crystals (not confirmed to be sorbate via 
Raman analysis) of theophylline are visible in the enlarged views. 
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Figure 3.9: Analysis of six tamoxifen salts formed on-chip (solid lines) and off-chip (dashed 
lines) using Raman spectroscopy.  Magnified views of the 930 - 1530 cm-1 range are provided to 
highlight the spectral differences between the different salts. 
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Figure 3.10: On-chip analysis of benzoate salt of tamoxifen. The Raman spectra for salt 
observed on-chip is overlaid with Raman spectra for salt off-chip, free tamoxifen, free benzoic 
acid, and empty chip to confirm the identity of the solid form crystallized on-chip.  
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Figure 3.11: Analysis of three theophylline cocrystals formed on-chip (solid lines) and off-chip 
(dashed lines) using Raman spectroscopy.  Magnified views of the 750 – 1150 cm-1 range are 
provided to highlight the spectral differences between the different salts.  
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Table 3.1: Dimensions of the evaporation channels for control over the rate of evaporation of 
the solvent. 
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Volume 
(nL) 
Time for complete 
evaporation (hrs) 
Rate of 
evaporation (nL/hr) 
Ac/L 
(µm) 
w  
(µm) 
L (mm) 
40 10 4 5.7 700 24.7 
10 4 5.7 860 30.34 
10 4 5.7 980 34.04 
240 25 9.6 14 1200 34.4 
240 50 4.8 7 600 34.4 
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Chapter 4 
DEVELOPMENT OF SOLVENT-RESISTANT MICROFLUIDIC PLATFORMS 
4.1. Introduction  
Over the last few decades, poly(dimethylsiloxane) (PDMS) has been extensively used for 
developing microfluidic devices using soft lithography, as the fabrication technique allows 
creation of high-resolution channel networks with excellent optical properties.1-3  The advent of 
multilayer soft lithography enabled the integration of active components, such as valves, pumps, 
and mixers by bonding together multiple patterned layers.2,4,5  A variety of normally open2,4,6-8 
and normally closed9-11 microfluidic valves have been used for various applications.6,12  Low 
Young’s modulus of PDMS (360-870 kPa) enables fabrication of valves permitting actuation at 
low pressures (1 – 10 psig9).  High resolution soft-lithography, facile ease of fabrication and 
interfacing allow development of platforms with complex and dense networks.4,7  Additionally 
PDMS is optically transparent, biocompatible, gas permeable and has low auto-fluorescence.1  
Due to the above advantages, PDMS-based microfluidics have been implemented in several 
biological studies (e.g., gene expression13, cell sorting14, immunoassays15, single cell 
analysis16,17, digital PCR18), and crystallization studies including crystallization of 
pharmaceutical compounds19 and biological macromolecules such as proteins6.  
Although, PDMS has several advantages such as low cost, excellent optical properties, 
high gas permeability, and biocompatibility, it suffers from two major drawbacks: limited 
solvent compatibility and permeability to small hydrophobic molecules.20,21  Implementation of 
PDMS has mostly been primarily limited to applications to involving aqueous media, due to its 
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incompatibility (issues with swelling and absorption) with many organic solvents.20  For studies 
involving organic media, hard non-polymeric materials such as glass or silicon, or alternative 
polymeric materials with elastomeric properties (similar to PDMS) have been explored.22,23  
Glass and silicon, however permit only limited control over fluid manipulation due to difficulties 
in incorporating moving components, such as valves and pumps.24,25  Alternatively, use of 
solvent-resistant polymers with low Young’s modulus, and a combination of hard materials and 
elastomeric solvent-resistant polymers is a promising platform compared to PDMS-based 
microfluidic devices.26-30  In addition, surface-passivation of the walls of PDMS microchannels 
with solvent-resistant materials has also been explored.31-35   
Pharmaceutical solid form screening involves the use of several organic solvents such as 
isopropyl acetate, ethanol, acetonitrile, methanol, heptane, hexane, DMSO, tetrahydrofuran, and 
toluene.  Although PDMS-based platforms are compatible with polar solvents, such as ethanol, 
methanol, acetonitrile, and isopropanol (as elaborated in chapter 2 and 3), these platforms are 
still incompatible with most of the aforementioned non-polar solvents.  In this chapter, efforts 
made towards developing microfluidic platforms that are compatible with a broad range of 
organic solvents have been discussed.  
 
4.2.  Literature Review 
Approaches that have been explored to overcome solvent incompatibility can be 
classified into three main categories: (1) use of surface coatings on the walls of PDMS 
microstructures that function as physical barriers to absorption and swelling of organic solvents, 
(2) use of alternative polymeric materials, which have a low Young’s modulus and are resistant 
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to organic solvents, and (3) use of hard non-polymeric materials, such as glass, in combination 
with solvent-resistant elastomeric materials. 
For surface passivation of PDMS microstructures, many coatings31,32,34-37 and surface 
modification techniques33 have been explored to minimize solvent absorption and enhance 
chemical resistance.  Some of these techniques were able to minimize solvent loss through 
PDMS, however at the cost of increase in actuation pressures for valves a requirement for 
complex fabrication procedure.  Kanai et al.35 reported passivation of PDMS microchannels with 
a perfluoro-amorphous polymer (CYTOP), and were successful in reducing swelling and 
absorption of organic solvents into PDMS to a certain extent.  Dam et al.36 explored the effects 
of Viton and Teflon AF coatings on PDMS, which provided moderate and high chemical 
resistance respectively.  Additionally, others have reported the use of glass coatings31,34, hybrid 
polymer coatings32 etc.  However, the above techniques for surface passivation of PDMS suffer 
from several limitations such as non-uniformity of the coating, lack of adhesion of the films and 
development of cracks in the films.  Also, most of the above efforts focused on development of 
single layer platforms.  The effect of coatings on the rigidity of PDMS, which is an important 
consideration for multilayer devices employing valves with flexible membranes, was not 
reported. 
Apart from using solvent-resistant coatings on PDMS, researchers have explored 
alternative elastomeric, polymeric materials that have superior chemical compatibility compared 
to PDMS (e.g., perfluoropolyethers (PFPE), liquid perfluoropolyether (SIFEL)) to develop 
multilayer microfluidic devices with valves.  Fluoroelastomers, particularly perfluorinated 
fluoroelastomers (where hydrogen is replaced with fluorine), are an attractive alternative to 
PDMS.  Multilayer microfluidic platforms employing PFPE based-elastomeric valves with 
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actuation pressures similar to those in PDMS-based devices have been reported.26,27,30  However, 
fabrication of such devices entails careful control over the ultraviolet exposure dose required 
during fabrication (as the layers are prepared separately and bonded via UV), and necessitates all 
the fabrication steps (spin coating, UV exposure, assembly, bonding) to be conducted in an 
oxygen-free nitrogen atmosphere.  Both these factors lead to complex fabrication procedures and 
low yields.38  Perfluoropolyethers are also an attractive alternative to PDMS.29,38,39  However, the 
extremely low surface energy and non-adhesive behavior of fluoropolymers lead to challenges in 
fabrication of high-resolution features and bonding of different layers.29  Recently, Naga et al.38  
reported application of  multilayer soft-lithography (MSL) procedures using perfluoropolyether 
(SIFEL 8115 X-71 A/B kit), a fluoroelastomer, to fabricate complex microfluidic devices.  
SIFEL has similar elastomeric and optical properties compared to PDMS and better chemical 
resistance, which make SIFEL a suitable candidate to replace PDMS in the development of 
solvent-resistant dense and complex microfluidic networks.  
With regards to development of microfluidic platforms made of hard non-polymeric 
materials with /without using elastomeric materials as membranes, many reports involving 
glass10,11,28,40-42, Teflon43, COC44,45 can be found in literature.  Use of glass and Teflon offer 
superior solvent resistance, as well as eliminate absorption of small hydrophobic molecules, 
which is inevitable in case of PDMS and other fluoroelastomers.  Du et al.41 have reported a 
glass-based slip-chip, where two glass layers were designed such that sliding two surfaces under 
FC-40 in different configurations enabled control over routing and mixing of fluids.  Grover et 
al.10 have reported a glass-based microfluidic device, where thin PDMS membranes were 
sandwiched in between two glass layers to minimize solvent absorption (by using reduced 
thickness of the PDMS layers) to the extent that some organic solvents could be used.  Willis et 
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al.28,40 modified these platforms and replaced PDMS membranes with amorphous 
fluoropolymers and PTFE-fluoropolymer laminates that offered excellent chemical resistance.  
However, fabrication of these laminates required complex fabrication.  Grover et al.11 replaced 
Teflon films with commercially available Teflon FEP (a fluorinated ethylene propylene, from 
DuPont) films, to circumvent the aforementioned fabrication issues.  These glass chips with 
Teflon membranes have been shown to minimized leakage with organic solvents.  However, 
glass micro-fabrication is labor and time-intensive, as the fabrication requires sophisticated 
infrastructure, and involves use of hazardous chemicals such as hydrofluoric acid (HF).  
Alternatively, hot-embossing of cyclic olefin copolymer (COC)44 sheets and Teflon43 (Teflon 
FEP and PFA (perfluoroalkoxy)) to create microchannels avoids the above issues with glass 
micro-fabrication.  Ren et al.43 recently reported whole Teflon based microfluidics comprising of 
flow and control layers made out of Teflon PFA, and Teflon FEP membranes sandwiched in 
between the layers.  These platforms are easy to fabricate and offer excellent solvent resistance.  
However, valve actuation in such platforms with complex and dense networks might be 
challenging due to the high Young’s modulus of Teflon.  
 
4.3.  Glass-based microfluidics 
Glass-based microfluidic platforms were explored as an alternative to PDMS-based 
microfluidic devices to minimize absorption of solvents and small hydrophobic molecules.  
These platforms were developed by adapting to research by Grover et al.10,11 (Figure 4.1). 
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4.3.1.  Fabrication procedure 
Borosilicate glass substrates (Nexterion Glass B uncoated, thickness 1.1 mm, Schott 
North America, NY) were cleaned by immersion in isopropanol and ultra-sonication for 
15minutes, immersion in nitric acid (15minutes), followed by rinsing in de-mineralized water 
and dry spinning.46  The front surface of the borosilicate glass was then evaporated with 2 layers: 
each layer comprised a chromium (Cr) and gold (Au) as 30nm and 150nm thick, respectively.  
Deposition of two layers of gold and chromium47 instead of one and venting of the evaporation 
chamber between deposition of the two layers improved adhesion and eliminated pin-hole 
defects observed with one-layer evaporation.48-50  After the deposition process, the coated glass 
wafers were selectively patterned with positive photoresist SPR 220-7.  The patterning procedure 
involved spin coating a thin layer of adhesion promoter, hexamethyldisilizane (HMDS), 
followed by spinning a 15 µm layer of positive resist, soft baking of the resist at 65°C and 115°C 
for 30 seconds and 90 seconds respectively, exposing under UV light (365 nm) for 50 seconds, 
and developing of the resist with MF 319 developer.  After patterning of the resist, Au and Cr 
were etched from the patterned surfaces using KI3 (KI: I2: H2O = 4g:1g:40 mL) and Cr etchant 
(Microchem Inc.) respectively.  An adhesive coating of vinyl tape was applied on the backside of 
the glass substrates prior to etching to prevent unwanted etching from the backside.  The glass 
substrate was then etched in 49-52% HF (Sigma Aldrich) for varying times resulting in different 
heights of the microchannels in the glass wafers (discussed in details later).  Post glass etching, 
the sacrificial layers comprising positive resist, Au, and Cr were removed with acetone, KI3 and, 
Cr etchant respectively.  Subsequently, holes were drilled at the inlets of the control lines in the 
control layer and at the inlets and outlets in the fluid layer with a diamond tipped drill bit 
(Amplex/Saint-Gobain Abrasives, Worcester, MA).  While drilling, water was used as a coolant 
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to avoid excessive heating that could crack the glass.  5:1 PDMS slabs were used as support 
layers for the fluid and the control layer.  These slabs were prepared by pouring PDMS on blank 
silanized silicon wafers followed by heating at 65°C for one hour.  The PDMS slabs were 
irreversibly bonded to the flat side of the glass wafers via treatment with oxygen plasma (Harrick 
Plasma).  Holes were punched at the inlets and outlets corresponding to the holes in the glass 
wafers.  Figure 4.2 shows the fabrication flow for glass microfluidic devices. 
 
4.3.2.  Membranes for valves 
Thin layer PDMS: A thin layer of PDMS was prepared by spin-coating 15:1 PDMS on 
blank silanized silicon wafers at different speeds (800, 1000, 1500, 2000 rpm) followed by 
curing at 65°C for 30 minutes.  A thick layer of PDMS was prepared by pouring 5:1 PDMS on 
blank silanized silicon wafers, followed by curing at 65°C for 30 minutes.  A 2.5” x 2.5” window 
was cut out of the PDMS slab to function as a handling layer and placed on top of the thin layer 
of PDMS, followed by heating at 65°C for 30 minutes to allow for bonding.  The PDMS mold 
bonded to the thin layer was then peeled off.  The thin PDMS layer was sandwiched between 
glass control and fluid layers, and the control layer was aligned onto the fluid layer.  To avoid 
leakage between the layers, the aligned device was sandwiched between plexi-glass blocks using 
screws.  In an alternative fabrication procedure, the PDMS layer was bonded irreversibly to the 
control layer via plasma bonding and then aligned onto the fluid layer. 
Thin layer of Polyimide  (PI-2545): A thin layer of polyimide (PI-2545, HD 
microsystems) was spin-coated at different speeds: 2500, 3000, and 3500 rpm on a cover glass.  
As PI swells due to moisture, a thin layer of the cover glass on sides was removed by etching in 
buffered oxide HF solution.  PI 2545 was then spin coated on cover glass and baked at 110°C to 
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partially cure the PI film.  The films were then cured in a vacuum oven, where the temperature 
was raised to 350°C and brought back to room temperature over a period of 6 hours.  The cured 
films were then either, removed from cover glass by swelling the films in water at room 
temperature overnight, or bonding the control layer to glass (using epoxy- amine bonding at 
80°C51-53) and then swelling the films in water.  Subsequent to introduction of amine and epoxy 
groups on the surfaces to be bonded, the surfaces were brought in contact to allow for 
irreversible bonding as illustrated in Figure 4.3.  However, the films were mostly observed to be 
wrinkled and prone to cracks.  
Teflon FEP films: In case of FEP films, the following grades and thicknesses of Teflon 
films were tested: FEP 50A, 100A, 100C-20, 100C, 50C (American Durafilms, MA).  The films 
were placed between the control and the fluid layer, and the assembly was sandwiched between 
plexi-glass blocks using screws.  The procedure as reported by Grover et al.11, was difficult to 
reproduce per se, as hot pressing of the C-20 film between the fluid and control layers led to 
cracking of the glass molds.  Thus, the bonding was neither strong enough nor very reliable. 
 
4.3.3.  Design and operation of the glass-based microfluidic devices 
The glass microfluidic devices were fabricated using the same design as that of salt 
screening chips described in chapter 2.  However, the numbers of wells in the design were 
reduced from 48 to 4, for initial testing.  The device was operated in a similar manner, except 
that the thin membrane was deflected into the control layer and the fluid was pulled via vacuum 
suction (Figure 4.4), instead of deflecting the valve stop in the fluid layer as employed in case of 
PDMS-based microfluidic devices.  
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4.3.4.  Results and Discussion 
Etching of glass is isotropic in nature.  This results in issues such as rounded 
microchannels instead of straight microchannels with increased dimensions (length and width).  
This made fabrication of dense networks in glass using the same design as that of salt screening 
chips described in chapter 2 very challenging.  Therefore, extensive characterization of glass 
etching was required prior to development of dense networks.  The following parameters needed 
to be optimized or adjusted for successful fabrication of glass devices: 
1. Gap between the chambers: To observe the effect of under etching, fluid layers with 
different gaps between the chambers (200 µm, 300 µm, and 400 µm) were explored.  
Small gaps can result in chambers connecting and cross talking to each other after 
etching.  It was observed that different gaps were optimal for varying etch heights.  Table 
4.1 shows approximate width of under-etch observed as a function of different etch 
heights.  Figure 4.4a shows fluid layer and control layer wafers with 300 µm gap after 6.5 
minutes of etch with 52% HF. 
2. Width of the control lines: Due to under-etching, the width of the control lines leading to 
the membrane tenting up into the control lines, in addition to the control valve area, 
which caused fluid leakage (e.g., see Figure 4.4b).  Therefore, the width of the control 
lines was decreased and the height of channels etched into the control layer was also 
reduced from 50 µm to 20 µm.  For the control lines wider than 100 µm, the whole 
PDMS or Teflon membrane tents into the control line.  Table 4.2, lists the effect of 
different etch-depths on control line widths.  Reducing the etch depth of the control layer 
helped in reducing leakage as seen in Figure 4.4c compared to Figure 4.4b. 
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3. Design modification to allow for alignment after etching: Due to under-etching the 
dimensions (length and width) of the microchannels in the fluid and control layers 
changed significantly.  This resulted in difficulties in aligning the control layer over the 
fluid layer as the design of the two layers did not account for the under-etch 
considerations.  To solve this problem, shorter and broader valves were designed for the 
control layer to account for reduction in the size of the valve stop and broadening of the 
fluid lines in the fluid layer, respectively.  After this modification, the alignment was 
good enough to allow for fluid filling and mixing as can be observed in Figure 4.4c. 
 
Testing of different films:  The glass devices worked well with PDMS membranes. The 
most reliable membrane thickness with respect to fabrication as well as operation was about 25 
µm.  Figure 4.4c shows filling of aqueous dyes in the device.  It was observed that leakage was 
minimized, but mixing of the food dyes was not efficient.  Teflon FEP membrane did not 
function reliably in terms of valve actuation.  It was difficult to observe valve actuation (due to 
high Young’s modulus of Teflon), avoid leakage and achieve good sealing between the layers.  
We were never able to get flat PI films, so those films could not be tested on chip.  
 
4.4. Conclusion 
A major problem with PDMS-based microfluidic devices is the high rate of solvent 
absorption and incompatibility with organic solvents.  In this chapter, recent-developments in the 
field of solvent-resistant microfluidic platforms were discussed.  Efforts in development of glass-
based microfluidic platforms were also addressed.  
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Use of several membranes and different fabrication techniques were explored for the 
development of glass devices, but none of the efforts have yielded an operational high-
throughput solvent-resistant platform.  In addition to pursuing glass-based devices, we are 
exploring alternative materials such as cyclic olefin copolymer or Teflon PFA43, where hot 
embossing can be used to transfer the patterns into these polymers.  We also plan to explore 
perfluoroether (SIFEL)38, as an alternative material to PDMS for making MSL devices. 
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4.5.  Figures and Tables 
	  
 
 
Figure 4.1: (a) Exploded and assembled illustrations of one FEP valve.  (b) In the cross-
sectional view of a single valve, the FEP film seals is sealed against the gap in the fluid channel 
when the valve is closed.  Applying vacuum to the displacement chamber (in the glass control 
layer) pulls the film away from the fluidic wafer and opens the valve allowing fluid flow through 
the channel in the glass fluidic wafer. (Figure adapted from Grover et al., Lab Chip, 2008) 11  
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Figure 4.2: Flow sheet showing the fabrication flow of glass-based microfluidic devices.  
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Figure 4.3: (a) Surface hydroxylation of polyimide and glass substrate by O2 plasma treatment 
for 1 min. (b) Aminosilane and epoxysilane anchoring of the polyimide and glass substrate. (c) 
Conformal contact of the two surfaces at 80°C for 1 hour. (Figure adapted from Tang and Lee, 
Lab Chip, 2010)51 
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Figure 4.4: (a) glass control and fluid layer with 300 µm gap between channels, after 6.5 
minutes etch (50 µm) (b) Filling in horizontal direction (b1) and vertical direction (b2), with 50 
µm features in control and fluid layers  (c) Filling in horizontal direction (c1) and vertical direction 
(c2), with 50 µm features in fluid layer and 20 µm in control layer. 
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Table 4.1: Dependence of under etch on etch depth and the optimum gap between the 
chambers in the fluid layer 
Etch time 
(minutes) 
Height etched 
(µm) 
Total under etch 
(µm) 
Optimum gap (µm) 
2.5 20 60-75 200 
3 25 80-90 200 
4.5 35 90-110 200 
6.5 50 130-160 300 
 
Table 4.2: Effect of etch depth on the width of the control line (CL) 
Etch time 
(minutes) 
CL width (µm) Etch height 
(µm) 
Final CL width (µm) 
2.5 25 20 ~90 
6.5 25 50 ~160 
2.5 70 20 ~135 
6.5 70 50 ~215 
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Chapter 5 
CONCLUDING REMARKS 
5.1. Summary 
This thesis reported the design, fabrication, and validation of hybrid microfluidic array 
chips for screening of solid forms of pharmaceutical parent compounds (PC) by free interface 
diffusion (FID), antisolvent (AS) addition, and evaporation-based crystallization and subsequent 
on-chip characterization of these crystal forms.  The microfluidic platforms were designed to mix 
PC and counter ion (CI) solutions or antisolvents in arrays of 24 (4x6 well architecture) or 48 
(4x12 well architecture) sub-microliter wells (90 to 200 nL/well).  The microfluidic platform 
allows 4 PC concentrations in a single solvent to be mixed combinatorially with 6 or 12 CI or AS 
solutions thereby enabling screening of 24 or 48 unique conditions respectively. Alternatively, a 
single PC concentration in a solvent can be subjected to different solvent evaporation rates.  
These platforms use significantly smaller quantities of PC as compared to traditional methods, 
thereby enabling the identification of multiple crystalline solid forms in the early stages of drug 
development when only limited quantities of PC (~ 10 mg) are available.  Reduction in the 
thickness of PDMS fluid and control layers and the use of solvent-resistant and solvent-
impermeable materials minimized solvent loss and allowed for on-chip characterization of the 
crystal forms by optical stereomicroscopy and Raman spectroscopy.  Several model 
pharmaceutical compounds such as naproxen, caffeine, ephedrine, tamoxifen, theophylline, and 
indomethacin, were crystallized to demonstrate the versatile application of these platforms 
towards crystallizing compounds with different modes of crystallization, namely, FID, 
antisolvent addition, and solvent evaporation. 
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5.2.  Future Work 
We are currently in the process of implementing the evaporation-based and FID-based 
microfluidic platforms to screen for solid forms (salts and cocrystals) of other model 
pharmaceutical compounds (PC).  We aim to utilize these platforms to study the effects of 
surfactants and other additives on crystal morphology and polymorphism.  We also plan to assess 
the developed platforms for compatibility with X-ray diffraction, which would enable on-chip 
elucidation of the molecular structures of the solid forms to help distinguish between salts, 
cocrystals, and free PCs.  We are also modeling super-saturation profiles, attained on addition of 
antisolvent, of PCs as a function of position on the well in the antisolvent screening to 
understand nucleation and growth kinetics of PCs.  Finally, we seek to improve the compatibility 
of these platforms with several non-polar solvents typically employed in pharmaceutical 
crystallization by exploring several routes for developing solvent-resistant microfluidic platforms 
with non-elastomeric materials such as cyclic olefin copolymer and Teflon PFA or elastomers 
like Teflon FEP. 
 
